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ABSTRACT 
CATHERINE C. CRUZ: An Alphavirus nsP1 determinant modulates Type I Interferon 
induction 
(Under the direction of Mark T. Heise, PhD.) 
 
 Alphaviruses are mosquito-transmitted viruses that can cause severe disease 
in both animals and humans.  The host type I Interferon (IFN) response plays a 
critical role in limiting alphavirus infections.  However, the specific interactions of 
type I IFN with that of the alphaviruses remain largely uncharacterized.  Therefore, 
to gain insight into these early interactions, this study addresses the role of genetic 
virulence determinants in modulating the host type I IFN response.  These analyses 
are based upon previous detailed mapping studies that identified a virulence 
determinant within the nsP1/nsP2 cleavage domain of the mouse adapted, 
neurovirulent Sindbis AR86 alphavirus that is critical for AR86 pathogenesis in vivo.  
We demonstrate that a Threonine to Isoleucine change at this position, leads to a 
mutant virus that robustly induces IFN independently of effects on viral replication or 
viral mediated shutoff of host macromolecular syntheses.  Furthermore, we 
demonstrate that the modulation in type I IFN induction is not specific to the Sindbis 
AR86 virus, as a similar mutation within the Ross River Virus, also leads to robust 
type I IFN responses, suggesting that the nsP1/nsP2 determinant may be 
fundamentally important for all alphaviruses.  Additional work has established that 
the nsP1/nsP2 determinant modulates type I IFN induction through the IPS-1 
signaling pathway, primarily mediated by the RIG-I and PKR receptors.  As RIG-I 
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and PKR recognize specific RNA ligands, such as free 5’ triphosphates on uncapped 
viral RNAs, we next determined whether the nsP1/nsP2 determinant would disrupt 
the viral capping apparatus.  We found increased synthesis of uncapped viral 26S 
subgenomic RNAs made within infected cells containing the nsP1/nsP2 mutation.  
Furthermore, the uncapped 26S RNAs differentially activated RIG-I which was 
phosphatase dependent.  Therefore, altogether, our data presents a novel 
mechanism in which a genetic determinant specifically enhances the viral capping 
apparatus in order to evade the host type I IFN receptors.  And disruption of the 
capping apparatus leads to the synthesis of uncapped RNAs that are efficiently 
recognized by the RIG-I and PKR host sensors to induce IFN to aid in the clearance 
of the viral infection.  
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ALPHAVIRUS DISEASE AND PATHOGENESIS 
 
Alphavirus epidemiology 
 Alphaviruses are mosquito-borne viruses from the family Togaviridae.  
Currently, there are more than 29 members of the Alphavirus genus that are widely 
distributed around the world (10, 27).  They are classified into two major groups 
according to their geological location and designated as “New World viruses” which 
are found primarily in North and South America, and the “Old World viruses” which 
are found in Europe, Asia, Australia, and Africa.  The New World viruses include 
Venezuelan equine encephalitis virus (VEEV), Western equine encephalitis virus 
(WEEV), and Eastern equine encephalitis virus (EEEV) and are often associated 
with fever and severe encephalitis that are sometimes fatal (5, 27).  The Old World 
viruses include Sindbis virus (SIN), Semliki Forest Virus (SFV), Ross River Virus 
(RRV), O’nyong-Nyong virus (ONN), and Chikungunya virus (CHIK).  Old World 
alphavirus diseases are more associated with fever, rash, and polyarthritis/myositis 
(68, 69).  Although Old World alphaviruses infections are generally not fatal, the 
arthritic symptoms can be quite debilitating, often lasting from several weeks to 
years (111).  Importantly, viruses in this group, such as CHIK, ONN, and RRV are 
capable of causing large-scale outbreaks affecting tens of thousands to millions of 
individuals, and should be considered significant emerging disease threats.  The 
successful re-emergence of these viruses are influenced by many factors such as 
increased populations, a decrease in herd immunity, and the expansion of 
transmission vectors (111).   
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 Alphaviruses exist in an enzootic life cycle, cycling between mosquito vectors 
and small mammals or birds that serve as amplification hosts.  Generally, the vector 
species and animal reservoirs used are believed to play a role in the distribution of 
certain members of alphaviruses (27).  For instance, Sindbis viruses that use birds 
as their amplification host, are found to be more widely distributed than other 
viruses, such as RRV and VEEV, which more predominately uses mammalian hosts, 
thus limiting their geographical spread.  Occasionally, alphaviruses will crossover 
from the mosquito into larger animals, such as humans and horses, to cause large 
scale epidemic diseases.  The potential for crossovers have caused serious global 
health concerns as outbreaks in the human populations have inflicted thousands to 
millions of people (30, 63, 114).  The latest CHIK virus outbreak occurred in 2005, in 
the island of La Reunion, infecting more than two hundred thousand people (106).  
Following this outbreak, more CHIK outbreaks were reported in the nearby Indian 
subcontinent and Africa as well as sporadic introduction into the Western 
Hemisphere (63, 74, 78, 111).  Additionally, a small outbreak in Italy occurred in 
2007 as an infected traveler from India arrived in a remote northern region, 
spreading the infection (3, 81). These incidents illustrate the growing threat that 
alphaviruses can emerge in new areas, since infected travelers can rapidly move 
into non-endemic areas, thereby perpetuating the outbreak. 
 
Animal Models of Alphavirus-Induced Disease 
 Mouse models have vastly increased our understanding of alphavirus-
induced diseases, defining the viral and host factors needed to sustain or combat 
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viral infections.  Use of these models has given insight into the replication patterns 
within mammalian hosts.  First, alphaviruses infections occur through the bite of an 
infected mosquito on the dermal layer of the skin, where alphaviruses will replicate in 
the residing Langerhans or dendritic cells (DCs).  The infected DCs then migrate to 
the draining lymph nodes (DLNs) where further viral replication takes place.  As 
replication increases, a high titer viremia in the blood stream occurs, facilitating 
spread into other organs and tissues.  In some cases, a high viremia also facilitates 
virus invasion of the central nervous system (5).  
 Several groups have developed mouse models that closely mirror human 
disease to study alphavirus pathogenesis (23, 33, 69).  These studies have led to 
the discovery of both genetic and host factors that are necessary for alphavirus to 
cause disease (68, 113).  The Sindbis group viruses are the most extensively 
studied.  In mice, most Sindbis viruses display an age dependent restriction of 
pathogenesis (27).  For instance, in neonatal mice, Sindbis virus infections result in 
lethal disease characterized by increased pro-inflammatory cytokine expression and 
high viremia in serum, muscles, brain, and in the spinal cord.  However, as the age 
of the mice increases, the replication of the virus is more restricted resulting in less 
severe or no disease.  More importantly, the majority of Sindbis viruses are avirulent 
in adult mice.  However, a few Sindbis strains are still pathogenic in adult mice 
causing neurovirulant disease.  Examples are the neuroadapted Sindbis virus (NSV) 
(107) and Sindbis AR86 (32, 98).  Detailed mapping studies have identified the 
genetic determinants responsible for the adult mouse neurovirulence of these 
viruses.  Suthar et al. (2005) performed comparative analyses between Sindbis 
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AR86 and a closely related Sindbis virus, GirdwoodS.A.  GirdwoodS.A. and AR86 
differ only by 22 single amino acid changes as well as a 18 amino acid sequence in 
the nsP3 protein that is only present in GirdwoodS.A.  Interestingly, in mice that are 
greater than 14 days old, GirdwoodS.A. virus was avirulent even when administered 
in high doses.  AR86, on the other hand, retains its neurovirulence regardless of the 
age of the animal.  Using their mouse models, Suthar et al. (2005) further defined 
AR86 adult mouse neurovirulence determinants, identifying four major virulence 
determinants in the viral genome.  The virulence determinants were a Threonine at 
nsP1 position 538, an 18 amino acid deletion at nsP3 386, a Cysteine at nsP3 537, 
and a Serine at E2 position 243 (104).  All four determinants were found to be 
essential for adult mouse neurovirulence.  Interestingly, the nsP1 determinant was 
found to be absolutely critical as a single codon change from a Threonine to an 
Isoleucine severely attenuated this virus (32, 104).  Furthermore, Heise et al. (2000) 
demonstrated that insertion of a Threonine into other avirulent Sindbis viruses was 
able to partially rescue virulence (32).  The exact role of this determinant in affecting 
mouse neurovirulence is currently not understood.   However, possible interactions 
with host factors will be highlighted in this dissertation.  The determinants for other 
neurovirulent Sindbis viruses have also been identified.  Studies with NSV identified 
a Histidine codon, position 55, in the E2 glycoprotein that plays a major role in the 
neurovirulence of this virus (107).  The neurovirulence of a related virus, Semliki 
Forest virus strain SFV4, was mapped to the genetic determinants within the 
nonstructural proteins (108).  Although the exact mechanisms for many of these 
virulence determinants to act in vivo are not clearly understood, these studies 
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provide insight into the genetic determinants that are located within the genome to 
impact the competence of an alphavirus to establish disease. 
 In addition to revealing genetic determinants that impact alphavirus 
pathogenesis, mouse models have also identified host factors that are necessary for 
controlling alphavirus replication (52, 86).  Studies using mice that are deficient for 
one or more molecules within the Interferon (IFN) pathway highlight the role for IFNs 
to control and inhibit alphavirus replication (84, 113).  The complete removal of the 
IFN system within mice generally results in lethal disease, even upon infection of 
avirulent viruses.  Therefore, an intact IFN system is a critical part of the host innate 
immune system to combat these viruses.  In the latter part of this chapter, we will 
further discuss the roles of the Type I IFN and the interactions with the alphavirus 
family. 
 
MOLECULAR BIOLOGY OF ALPHAVIRUS 
 
Alphavirus particle structure and cell entry 
Alphaviruses are enveloped particles enclosing one copy of a single stranded 
positive sense genome.  The genome is encapsidated by the viral capsid proteins 
forming a nucleocapsid core structure.  The nucleocapsid core is further surrounded 
by a lipid bilayer derived from the host cell plasma membrane.  The viral 
glycoproteins, E1 and E2, are embedded within the outer lipid shell.  The E1 and E2 
glycoproteins form heterodimers and assemble into 80 trimeric spikes forming an 
icosahedral lattice structure (T=4 symmetry) at the virus surface (40).  The 
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glycoproteins primarily mediate entry of the virus into a host’s cell where the E2 
glycoprotein is responsible for receptor attachment and the E1 glycoprotein 
mediates fusion of the virus with the cell membranes.  Although it is thought that E1 
may also play a role in receptor attachment.  Currently, the process of alphavirus 
entry into a host cell is still being debated.  Though, there are two main hypotheses.  
One hypothesis is that the virus utilizes receptor-mediated endocytosis, although the 
exact alphavirus receptor(s) remains elusive.  In this pathway, the alphavirus E2/E1 
glycoprotein engages a receptor.  Then, the virion is internalized within a cellular 
endosome.  As the pH within the endosome lowers, the E2/E1 glycoproteins 
undergo a conformational change exposing a fusion peptide on the E1 glycoprotein.  
The fusion peptide inserts into the plasma membrane, creating a fusion pore.  The 
viral nucleocapsid core is then inserted into the host cytoplasm.  However, recent 
evidence counteracts this theory by demonstrating that a low pH environment is not 
necessary for fusion (72).  Thus, an alternative pathway for alphavirus entry has 
been proposed to occur at the cell surface facilitating fusion of the virus membrane 
with that of the cell membrane.  Consequently, a fusion pore is created allowing 
insertion of the nucleocapsid core containing the viral genome.  Upon entry, the host 
cellular translational machinery will translate the viral genome that initiates viral 
replication.  
 
Genome organization and replication 
The alphavirus genome consists of a single stranded positive sense RNA that 
is approximately 11-12Kb long.  The genome contains a 5’-!methylguanylate cap 
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structure and a 3’-polyadenylate (poly-A) tail similar to those found on host cellular 
mRNAs. The genome encodes two open reading frames where the 5’ 2/3 encodes 
for the nonstructural proteins and the 3’ end encodes for the structural proteins.  The 
structural proteins are tightly regulated by an internal 26S subgenomic promoter that 
transcribes short 26S RNAs that are identical to the 3’ end of the viral genome.  The 
26S RNAs, like those of the full-length genomes, are also capped and 
polyadenylated.  The 26S RNAs are made in 5-fold molar excess to that of the full 
length genomic RNAs for translation of the structural proteins that are required for 
virion assembly (51).  Additionally, the alphavirus genome also encodes regulatory 
segments.  These segments consist of four conserved sequence elements (CSE) 
found throughout the alphavirus genomes.  The most highly conserved CSE is found 
in a 19-nucleotide region at the 3’ untranslated region (UTR), immediately preceding 
the poly (A) tail.  The 3’ CSE serves as a strong promoter to facilitate negative sense 
RNA synthesis (29).  The other CSEs are found at the 5’ UTR and at the junction 
across the subgenomic promoter to facilitate synthesis of the full-length positive 
sense and 26S RNAs.  Furthermore, mapping studies have demonstrated that the 
CSEs recruit both host and viral factors necessary for viral replication (46, 101). 
There are four nonstructural proteins encoded by the virus genome.  The 
major function of the nonstructural proteins is to replicate and transcribe the viral 
genomes although some individual nsP proteins can play additional roles in an 
infected cell (50, 82).  NsP1 is a palmitoylated protein that is tightly associated with 
the cytoplasmic surface of the plasma membranes, endosomes, and lysomes, 
thereby anchoring the replication complex to the cell membranes (49, 99).  NsP1 is 
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also a guanine-7-methyltransferase that exhibits guanylyltransferase activities and is 
involved in capping the full-length positive sense and 26S RNAs.  NsP2 is a 
multifunctional protein that encodes for several distinct functions such as; a papain-
like protease that mediates the cleavage of the nonstructural proteins, a nucleoside 
triphosphatase (NTPase), which is essential for viral replication, an RNA helicase, as 
well as a 5’-triphosphatase that facilitates the capping of the viral RNA.  The nsP2 
protein also contains nuclear localization signals and ~50% can be found in the 
nucleus (67).  The nsP3 protein is a phosphoprotein that is important for viral 
replication, however, its exact function is unknown (110).  And finally, the nsP4 
protein is the RNA-dependent RNA polymerase that mediates synthesis of the viral 
RNAs. 
Upon infection by alphavirus, the viral genome is immediately translated to 
produce two nonstructural polyproteins, P123 and P1234.  The P123 polyprotein is 
generated by an opal termination codon encoded between the nsP3 and nsP4 gene.  
Translational readthrough of the opal codon occurs with 10-20% efficiency, 
generating the P1234 polyprotein (34).  The nonstructural polyproteins are then 
cleaved into their mature nonstructural proteins by the viral nsP2 protease.  There 
are three conserved cleavage domains that reside between the nsP1/2, nsP2/3, and 
nsP3/4 polyprotein.  Each cleavage domain is conserved among the alphaviruses 
and differentially recognized by the nsP2 protease (101).  The coordinated 
sequential cleavage of the nonstructural polyproteins that proceeds next is well 
organized to tightly regulate the synthesis of the viral genomes.  First, nsP4 is 
cleaved from the P1234 polyprotein through nsP2 cis cleavage.  Then, P123 
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associates with mature nsP4, to form a viral replication complex that binds to the 
conserved 19-nucleotide sequence at the 3’-UTR of the positive sense genome.  
The P123-nsP4 complex will then mediate full-length negative sense RNA synthesis, 
using the positive sense RNA as its template.  As P123 polyproteins accumulate, the 
nsP2 protease will then mediate trans cleavage of the polyproteins.  The first trans 
cleavage occurs between P1/2, thus creating mature nsP1, polyprotein intermediate 
P23, and nsP4.  These proteins, in association, continue to make negative sense 
RNAs.  However, they are also capable of binding to the minus sense RNA at the 5’-
CSE, to begin generating full-length positive sense RNAs.  Additionally, 26S RNA 
synthesis also occurs, though the 26S RNA levels are lower than that of the full- 
length positive sense RNAs (51, 59).  Finally, trans cleavage of P23 occurs last, 
generating mature nsP1, nsP2, nsP3, and nsP4 proteins.  The mature nsPs continue 
to synthesize full length positive sense RNAs, but in addition, will also bind to the 
internal subgenomic promoter to mediate full synthesis of short 26S RNAs.  As 
mentioned before, a five-fold ratio of 26S RNA is made to the full-length positive 
sense RNA.  The 26S RNAs encode for the structural proteins that are then 
translated by the host cellular translational machinery.  The final cleavage between 
P23 is thought to end negative stand RNA synthesis, thus switching completely to 
full-length RNA and 26S RNA synthesis (51).  In agreement with this model, minus 
RNA strand synthesis usually occurs early and then ceases about 4-7 hours post-
infection (59).  Since the mature nonstructural proteins are cleaved into their mature 
forms and do not undergo further cleavage, synthesis of full length positive sense 
and 26S RNAs occurs throughout the remainder of the virus life cycle. 
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Virus assembly and budding 
The structural proteins are translated from the 26S RNAs as a single 
polyprotein.  The polyprotein encodes, in this order, for the capsid, the glycoproteins 
(E3, E2, and E1), and the 6K protein.  The capsid protein possesses serine protease 
activity and is immediately cleaved from the polyprotein by autoproteolytic cleavage 
(64).  Cleavage of the capsid protein exposes a signal sequence within the PE2 
polyprotein (E3/E2 precursor) that directs the polyprotein into Endoplasmic 
Reticulum (ER) and the Golgi (40, 56).  A second signal sequence within the 6K 
protein allows continuation of the translocation of the E1/6K polyprotein into the ER 
(65).  As the polyprotein translocates across the ER, it is further processed to 
release the E1 and 6K proteins.  The PE2 is cleaved last by host furin proteases to 
generate E3 and E2 glycoproteins.  As the structural proteins translocate across the 
ER and Golgi, they are post-translationally modified.  High mannose and complex 
carbohydrates are added to the glycoproteins as the proteins as the structural 
proteins are translocated to the cell surface.  Meanwhile, the previously released 
capsid proteins will immediately bind to the full-length positive sense genomes to 
form the nucleocapsid core.  This binding is specific for the genomic RNA as the 
capsid protein recognizes a specific packaging genome located within the nsP1 or 
nsP2 coding sequences (14, 112).  As the 26S RNAs do not contain these regions, 
they are not encapsidated.  The nucleocapsid core consists of ~240 capsid proteins 
surrounding a single genome, thus creating a stable complex.  The nucleocapsid 
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core then binds to the viral glycoproteins where the virus particle finishes assembly 
and buds from the plasma membrane.   
ALPHAVIRUS INTERACTIONS WITH THE INNATE IMMUNE SYSTEM 
 
The Type I Interferon Signaling Pathway  
Type I Interferons (IFNs) are an important component of the host’s innate 
immunity, acting as the first line of defense against invading pathogens.  Interferons 
were initially discovered as a cytokine that interfered with Influenza A virus infection 
indicating antiviral properties (38).  Since their discovery, a vast number of studies 
have furthered our understanding of how IFNs act.  It is now well established that 
IFNs induce expression of antiviral genes that act to limit viral replication and spread 
through mechanisms such as host-mediated shutoff of protein translation, viral 
nucleic acid degradation, and release of cytokines to shape the downstream 
adaptive immune response to clear the virus (87, 103).  Furthermore, it has been 
clearly demonstrated that the host Type I IFN is essential for mounting a robust 
response against virus infection as mice that have a genetic defect for type I IFN 
signaling are highly susceptible to many virus infections (87).  Therefore, the overall 
importance of Type I IFN to the host is critical. 
The Type I IFNs in humans comprise of 7 subtypes, IFN-!, IFN-", IFN-#, IFN-
$, IFN-%, IFN-& and IFN-', although IFN-!" are the most well studied.  It has been 
demonstrated that many different cell types can secrete IFN-!" cytokines, though 
the recognition receptors that mediate these responses differ.  In humans, there are 
a total of 13 IFN-! subclasses (14 in mice) and only one IFN-".  Upon recognition of 
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a viral infection, the type I IFN system will respond to the virus by activating a 
signaling cascade leading to IFN-" transcription.  Virus recognition is mediated by 
the host pattern recognition receptors (PRRs).  Host PRRs recognize specific virus 
motifs present on the virus particles or generated during viral replication.  These 
motifs are referred to as pathogen-associated molecular patterns (PAMPS) and 
include viral glycoproteins and nucleic acids.  Upon binding of a PRR to its PAMP, 
specific signaling pathways that consist of various co-adaptor and scaffold proteins 
are activated.  The different PRR signaling pathways ultimately converge to activate 
the IKK and TBK1/IKK$ kinases, which in turn, activates the transcription factors, 
nuclear factor kappa B (NF-#B) and Interferon Regulatory Factor 3 (IRF-3), 
respectively.  NF#-B is normally kept in an inactive state by the I#B protein.  Upon 
IKK activation, IKK phosphorylates I#B, resulting in I#B polyubiquitylation and 
degradation, thus releasing NF-#B.  NF-#B will then translocate to the nucleus to 
upregulate pro-inflammatory cytokine expression and IFN induction (83).  IRF-3 
activation occurs a little differently.  IRF-3 is ubiquitously expressed within a cell 
shuttling in and out of the nucleus.  However, activation of the TBK1 and IKK$ 
kinases phosphorylates the C-terminal end of IRF-3.  Phosphorylated IRF-3 will then 
dimerize, translocate to the nucleus, and associate with co-activator CBP/p300 to 
bind to IRF-3 specific promoters.  The binding of an enhancesome made up of IRF-
3/CBP/p300, NF-#B, and the ATF-2/c-Jun transcription factors, specifically activates 
the IFN-B promoter upregulating IFN-" mRNA transcription (35).  
The IFN-" cytokine is then secreted from the cell where it will bind to the IFN-
! Receptor complex (IFNAR1 and IFNAR2) that is present on nearby adjacent cells 
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or on its own cell membrane.  This in turn, activates the Janus activated kinase 
(JAK) and Signal transducer and activator (STAT) pathways.  Activation of the JAK-
STAT signaling pathway results in the phosphorylation of the STAT-1 and STAT-2 
proteins, and in association with IRF-9 (forming the ISGF3 complex), translocates to 
the nucleus to bind to several Interferon stimulated response elements (ISREs) in 
DNA to initiate transcription of IFN stimulated genes (ISGs).  There are 
approximately more than 300 ISGs that are upregulated by type I IFNs.  However, 
only a few have been characterized for their antiviral activities.  One ISG encodes for 
IRF-7.  IRF-7 is a transcription factor with similar structural homology to IRF-3 that 
acts as a positive feedback loop for the type I IFN response.  IRF-7 is 
phosphorylated by the TBK1/IKK$ kinases, resulting in IRF-7 homodimerization and 
translocation into the nucleus to stimulate IFN-! transcription.  Additionally, 
phosphorylated IRF-7 can bind to phosphorylated IRF-3, forming heterodimers that 
can bind to IFN-" promoter, thus amplifying the type I IFN response.  Therefore, the 
type IFN response can be divided into 2 distinct phases: 1) An induction phase 
mediated by pattern recognition receptors and 2) an amplification phase that is 
dependent upon IFN receptor signaling through the JAK/STAT pathway.  Although, it 
should be noted that some PRRs directly stimulate IRF-7 activation to induce type I 
IFN.   
 
Pattern Recognition Receptors 
The IFN induction phase is mediated by Pattern Recognition Receptors 
(PRRs) that can recognize different pathogen-associated molecular patterns 
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(PAMPs) expressed by viruses.  The PRRs that recognize viruses include the Toll-
Like Receptors (TLRs), the retinoic acid inducible gene (RIG-I)-Like Receptors 
(RLRs), as well as the double stranded RNA dependent Protein Kinase R and 2’-5’-
oligoadeny-late synthetases (OASs).  TLRs are transmembrane receptors with 
leucine-rich repeats that recognize viral PAMPs at the cell surface or within 
endosomal compartments.  Each TLR is specific for a particular PAMP recognition, 
such as lipids, proteins, and nucleic acids.  Examples of viral PAMPs and their 
corresponding TLR are dsRNA (TLR3), ssRNA (TLR7 and TLR8), and 2(-deoxyribo 
(cytidine-phosphate- guanosine) (CpG) DNA (TLR9).  Although, TLR4 is thought to 
mainly recognize bacterial lipopolysaccharides, reports have demonstrated a critical 
role for TLR4 in inhibition of respiratory syncytial virus (48), suggesting that TLR4 
does play a role in fighting viral infections.  The TLRs use four TIR-domain-
containing adaptor molecules to activate distinct downstream activation pathways to 
induce IFN !" and pro-inflammatory cytokine responses via NF#-B activation.  The 
four co-adaptors are MyD88, TIRAP (also known as Mal), TICAM-1 (also known as 
TRIF), and TRAM.  All the TLRs, with the exception of TLR3, utilize the MyD88 
dependent signaling pathway to activate NF-#B.  In addition, TLR7, 8, and 9 can 
activate IRF-7 to mediate IFN-! induction.  TLR3, however, solely uses the TICAM-1 
molecule to induce IRF-3 activation and inflammatory cytokines production.  TLR4, 
on the other hand, uses all four co-adaptors activating both the TICAM-1 and MyD88 
dependent signaling pathways.  However, TLR4 mediated type I IFN induction is 
strictly dependent upon TICAM-1 signaling, whereas induction of the pro-
inflammatory response requires both TICAM-1 and MyD88 pathways (36). 
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 The RIG-I-Like Receptors comprise of three RNA helicases, RIG-I, melanoma 
differentiation associated gene 5 (MDA-5) and the laboratory of genetics and 
physiology 2 (LGP2).  All three RNA helicases reside exclusively in the cytosol of a 
cell and encode a C-terminal DExD-box RNA helicase and ATPase dependent 
domain (88).  RIG-I and MDA-5, however, encode two N-terminal caspase 
recruitment domains (CARD).  The CARD domains facilitate the recruitment of the 
IFN-promoter stimulator (IPS-1; also known as MAVS, VISA, and Cardif) (44, 66, 94, 
116) co-adaptor that is present on the mitochondrial membranes.  IPS-1 also 
encodes a CARD domain, thus homotypic CARD-CARD interactions with RIG-I or 
MDA-5 then lead to the recruitment of additional signaling factors to mediate the 
downstream activation of the IKK and TBK1/IKK$ kinases, thus activating both NF-
#B and IRF-3 (39, 73, 77, 123).  RIG-I and LGP2 also encode a repressor domain 
(RD) at the C-terminal end of the protein, whereas MDA-5 does not, indicating that 
the RNA helicases may have different regulatory mechanisms (89).  It has been 
proposed that RIG-I normally remains in an auto-inhibitory state that is regulated by 
the RD domain.  Upon binding of the RNA substrate to its C-terminal end (RD), RIG-
I undergoes a conformational change exposing its CARD domains, thus leading to 
RIG-I activation.  Further, the RD domain of RIG-I has also been linked to the 
distinct binding specificities for RIG-I.  Therefore, the presence of an RD domain 
may explain why RIG-I and MDA-5 can mediate IFN induction to distinct viruses.  
The LGP2 helicase also encodes the RD domain, although it lacks the N-terminal 
CARD domains that would allow LGP2 to interact with IPS-1.  The LGP2 protein can 
form complexes with both RIG-I and MDA-5.  Interestingly, the LGP2 RD domain 
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inhibits RIG-I mediated IFN signaling and not that of MDA-5.  Thus, similar to RIG-I, 
LGP2 can also recognize the same RNA ligands, however, with greater affinity.  
Therefore, it is believed that LGP2 acts as a negative regulator to RIG-I inhibiting its 
IFN signaling as a negative feedback mechanism.  However, LGP2 has also been 
demonstrated to be a positive regulator of EMVC mediated IFN induction, a pathway 
that is strictly mediated by MDA-5 (118).  Therefore, the exact role(s) of LGP2 has 
not been clearly defined.   
Although both MDA-5 and RIG-I activate the same signaling pathways, it is 
clear that the RNA helicases discriminate between viruses, therefore diversifying the 
recognition of the IFN response.  Several studies using RIG-I, MDA-5, or IPS-1 
genetically deficient mice have reported the exclusive role for either RIG-I or MDA-5 
to recognize specific viruses (41, 47).  Examples of viruses that require RIG-I to 
mediate IFN induction include Influenza, Sendai virus, and Hepatitis C virus (43, 
102).  MDA-5, on the other hand, induces IFN to encephalomyocarditis virus 
(EMCV) and to synthetic poly IC RNA substrates (22).  However, in addition to 
recognizing different RNA viruses, it was further demonstrated that RIG-I and MDA-5 
could overlap in their virus recognition (37, 42, 57).  For example, both RIG-I and 
MDA-5 can induce IFN responses to West Nile Virus, Measles virus, and Reoviruses 
(13, 37, 42).  The exact mechanism(s) underlying virus specificity is hypothesized 
that different viral RNA structure motifs exist between these viruses, thus allowing 
RIG-I and MDA-5 to discriminate between RNA ligands.  In the case with 
Reoviruses, different RNA ligands are exposed during virus replication to activate 
both RIG-I and MDA-5.  In support of this theory, it was determined that the reovirus 
18 
genome consists of ten dsRNA segments of varying sizes where the long dsRNA 
segments mainly activated MDA-5 and the short dsRNA segments (less than 2Kb) 
activated RIG-I (42).  These studies therefore suggest that a length dependent 
discrimination is employed by the two RNA helicases to recognize various viruses.  
However, a length dependent recognition by RIG-I does not explain RIG-I 
recognition of viruses with long single stranded genomes (such as West Nile Virus 
whose genome is ~11Kb).  Therefore, it is hypothesized that in addition to short 
dsRNAs, other RIG-I RNA ligands must exist (88, 103).  Therefore, a number of 
intensive studies have been initiated to identify the natural RNA ligand to RIG-I.  
Thus far, several RNA ligands with different structural motifs have been proposed, 
although there are conflicting reports.  Therefore, this area of research is still heavily 
debated.  Some examples of RIG-I ligands are free 5’-triphosphates, 3’-
monophosphates, as well as 5’-monophosphates present on either ssRNA or dsRNA 
(60, 75).  Additionally, viral RNA ligands may also encode nucleotide sequence 
specificities that facilitate RIG-I binding such as poly U/A tracts found within the 
3’UTR of flaviviruses (90, 109).  It is important to note though, that many of these 
studies utilized chemically synthesized RNAs with modified phosphates in their 
analysis.  Therefore, a major argument presented within the field is that these RNA 
substrates do not reflect the natural viral RNAs made within an infected cell.  Thus, 
several studies have identified potential RIG-I ligands by extracting viral RNAs made 
within infected cells and transfecting those RNAs into RIG-I deficient or wild type 
cells (75, 79).  Using this approach, Rehwinkel et al. (2010) found that Influenza viral 
genomic RNAs were the major activators of RIG-I and that RIG-I activation required 
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the presence of a 5’ triphosphate.  Furthermore, the authors were able to 
demonstrate that the viral RNA transcripts and the RNase L cleaved RNAs were 
minor contributors to RIG-I activation.  Therefore, 5’-triphosphates present on 
dsRNAs and ssRNAs are proposed to be the natural RIG-I ligands.  This hypothesis 
is further supported by the fact that 5’-triphosphates are naturally generated during 
virus replication in the cytoplasm of infected cell.  Host mRNAs are normally post-
transcriptionally modified within the nucleus to contain a 5’ cap structure or a 5’-
monophosphate before they are exported into the cytoplasm.  Therefore, the 5’-
triphosphates on host mRNAs are never exposed to RIG-I.  In support of this, 
Rehwinkel et al. (2010) also demonstrates that Influenza viral RNA transcripts, which 
are modified with an attached 5’-cap, do not activate RIG-I.  Accordingly, the RNA 
helicases are able to discriminate self from non-self RNAs.  The RNA substrates for 
MDA-5 have also been extensively studied and are found to be long dsRNA and 
ssRNA that consist of large secondary structures (22, 76).  However, activation of 
MDA5 can occur in the presence or absence of phosphates. 
 Another set of PRRs that play roles in mediating IFN induction to viruses are 
the dsRNA dependent PKR and RNase L proteins.  PKR and RNase L are Interferon 
stimulated genes though both proteins are constitutively expressed at basal levels in 
most tissues.  PKR encodes two dsRNA binding domain as well as a regulatory 
kinase domain.  PKR can recognize dsRNA that are longer than 30 nucleotides 
regardless of the nucleotide sequence (71).  Although it has been demonstrated that 
PKR can recognize shorter RNAs, such as 16 nucleotide ssRNAs that form stem 
loop structures (70).  However, it was found that the presence of a 5’-triphosphate 
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on the stemloop RNA was necessary for PKR recognition.  As PKR is highly 
upregulated after IFN-!" induction, it is generally thought to participate as an anti-
viral factor during the IFN amplification phase.  However, recent evidence has 
suggested that PKR can act directly as a PRR to recognize West Nile Virus (21) 
inducing IFN-" synthesis possibly through an NF-#B pathway that is independent of 
RIG-I signaling.  PKR has also been demonstrated to induce IFN to an Vaccinia 
Virus E3L mutant (119).  The Vaccinia virus E3L protein is a known inhibitor of IRF-3 
and IRF-7 phosphorylation.  Thus, the authors used the E3L mutant to circumvent 
the viral IFN antagonist properties to address the PRRs that mediate IFN induction.  
The authors found that PKR could recognize vaccinia virus dsRNA intermediates to 
induce IRF-3 phosphorylation.  Furthermore, they found that IRF-3 phosphorylation 
was dependent upon the IPS-1 signaling pathway.  However, the roles for PKR to 
cooperatively signal IFN induction with the RLR helicases have not been defined.  
Therefore, the exact mechanism for PKR to mediate IRF-3 activation via the RLR-
IPS-signaling pathway remains unknown.   
 Recent evidence suggests that another ISG, RNase L, can also play a role in 
the IFN induction pathway.  RNase L is an endoribonuclease that cleaves single 
stranded regions of RNAs into small RNA cleavage products.  Studies that were 
performed in RNase L deficient mouse embryonic fibroblast cells demonstrated a 
reduction in the IFN-" response to transfected poly IC ligands or upon infection with 
Sendai virus suggesting a small role to modulate IFN responses.  The authors 
further demonstrated that the small cleavage products produced from functionally 
RNase L were capable of inducing IFN-" production.  Also, IFN induction was 
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dependent upon an intact IPS-1 signaling pathway.  Interestingly, the small RNA 
cleavage products were less than 200 nucleotides long, contained 3’-monophospate 
rather than 5’-triphosphates, and signal IFN-" induction through both the MDA-5 and 
RIG-I RNA helicases (60).  Therefore, RNase L is a PRR that is activated by viral 
dsRNA replicates and indirectly induces IFN production by amplifying the responses 
of the RLRS. 
 Alphaviruses are potent IFN inducers in vivo (15).  However, the pattern 
recognition receptors that mediate these responses are not clear.  Several studies 
using Sindbis and Chikungunya viruses have demonstrated that the IPS-1 signaling 
pathway is important for alphaviruses to mediate IFN induction (6, 93).  However, 
these studies also report conflicting evidence for which upstream PRR is responsible 
for recognizing their viruses.  Burke et al. (2009) demonstrated that both MDA-5 and 
PKR, but not RIG-I, contribute to IFN induction upon Sindbis infection of primary 
mouse embryonic fibroblast cells (6).  It should be noted, though, that these studies 
were performed using a non-cytopathic Sindbis NsP2 mutant (39nc) to characterize 
their results.  Therefore, we cannot exclude the possibility that recognition of the wild 
type Sindbis virus would be mediated through different receptor combinations.  
Schilte et al. (2010), on the other hand, demonstrates that wild type Chikungunya 
infections of similar fibroblast cells are mediated by both RIG-I and MDA-5 (93).  
Therefore, it can be inferred that multiple receptors may contribute to the overall 
recognition of alphaviruses or that different members of the alphavirus family 
differentially activate IFN induction.  Regardless of the PRR that is responsible for 
mediating IFN induction, activation of the type I IFN leads to upregulation of genes 
22 
capable of inhibiting alphavirus replication, and thus making type I IFNs absolutely 
essential for alphavirus control. 
 
Interferon stimulated genes to limit alphavirus replication 
 As discussed previously, IFN-!" induction results in the stimulation of 
hundreds of ISGs.  These ISGs encode for numerous proteins that act as PRRs to 
detect viral replication, transcription factors to facilitate IFN production and 
amplification, and anti-viral effectors that limit viral spread.  Thus far, the functions of 
only a few anti-viral effectors have been characterized to actively inhibit virus 
infections.  There are four major anti-viral effectors that have been the most 
extensively studied.  Some have also been demonstrated to play a role in inhibiting 
alphavirus infections in vivo (87).  They are the IFN-stimulated protein of 15kDa 
(ISG15), dsRNA dependent PKR protein, the GTPase myxovirus resistance 1 (Mx1), 
and the endoribonuclease L (RNase L).  Therefore, examples of ISGs and how they 
exert anti-viral activities are discussed next. 
 ISG15 is a ubiquitin homologue that regulates the expression of more than 
100 target proteins.  These target proteins participate in various cellular pathways 
such as RNA splicing, cell cycle regulation, and cell cytoskeleton organization (121).  
ISG15 is conjugated to target proteins by three conjugation enzymes, an E1-like 
ubiquitin-activating enzyme (UBE1L), and E2 ubiquitin conjugating enzyme 
(UBCH8), and an E3 ubiquitin ligase (HERC5).  The attachment of the ISG15 
molecules is similar to that for ubiquitin, thus ISG attachment is referred to as 
ISGylation.  However, unlike ubiquitylation, ISGylation does not lead to the 
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degradation of the target protein.  Instead, ISGylation modifies a protein’s function 
similarly to the activating effects found by the K63-linked ubiquitin attachment.  As 
an example, ISGlyation of IRF-3 prevents virus mediated IRF-3 degradation, thus 
ensuring robust IFN-" production.  Additionally, recent reports that ISG15 
conjugation to the NS1 protein of Influenza A viruses also leads to an inhibition of 
virus replication.  Therefore indicating a specific targeting of a viral IFN antagonist 
(122).  ISG15 also plays an important role in vivo to several viruses, including 
Sindbis viruses (52, 53).  Mice that are deficient for the Interferon ! receptor (IFNAR) 
are readily susceptible to Sindbis virus infections and will succumb to disease.  
However, using a recombinant Sindbis virus to express the ISG15 gene from a 
duplicate 26S promoter will protect the IFNAR-/- deficient mice from the Sindbis 
infections.  Furthermore, a similar ISG15 rescue in ISG15-/- mice also displayed a 
protective phenotype against a lethal Sindbis infection (53).  Although ISG15 is 
clearly important for Sindbis infection, the exact mechanisms to protect these mice in 
vivo are not fully understood.    
PKR is a member of a kinase family that regulates protein translation in 
response to cellular stress.  PKR is normally kept in an inactive state within the cell 
by its N-terminal kinase domain.  Upon binding to its viral ligand, PKR undergoes 
autophosphorylation and dimerization, leading to PKR activation.  Active PKR 
dimers will then bind and phosphorylate the subunit of the eukaryotic translation 
initiation factor 2 (eIF2!) at serine 51, resulting in a halt in global protein translation.  
This process then leads to a decrease in the viral proteins that are necessary for 
viral replication and assembly.  PKR has been demonstrated to mediate protection 
24 
to several viruses (1).  Mice deficient for both the PKR and RNase L gene were 
highly susceptible to a lethal strain of West Nile Virus, corresponding with enhanced 
viral titer in the draining lymph nodes and sera, as well as earlier viral entry into the 
central nervous system (92).  Furthermore, PKR is required for the IFN-mediated 
resistance to Vesicular stomatitis virus (100).  PKR also mediates partial protection 
against Sindbis viruses by restricting early viral replication in the draining lymph 
nodes (DLN) of infected mice and in in vitro dendritic cell cultures (86).  Interestingly, 
although PKR exhibited some antiviral effects, unlike previous results with IFNAR 
deficient mice, PKR was not absolutely required to mediate full protection of mice 
from Sindbis viruses.  These studies suggest that an alternative, IFN!" dependent 
pathways are responsible for restricting Sindbis viruses in vivo.  Therefore, studies 
to identify alternative ISGs that inhibit alphaviruses are being pursued. 
There are several encoded ISGs that have been identified to inhibit Sindbis 
replication.  Ryman et al. (2005) used Affymetrix microarray technology to identify 
approximately 44 potential genes that are candidates for IFN-induced antiviral ISGs 
that act to inhibit Sindbis viruses, independently of the PKR and RNase L pathways 
(85).  Some of the identified genes are ISG15, the zinc finger antiviral protein (ZAP), 
and viperin (120).  The ZAP protein was originally isolated as an antiviral protein that 
inhibited Moloney murine leukemia virus (MMLV) (16).  Recently, ZAP was also 
demonstrated to inhibit multiple members of the alphavirus family, including Sindbis, 
RRV, SFV, and VEEV (2).  Although, ZAP inhibition of Sindbis virus was the 
strongest of the alphaviruses tested.  The ZAP protein was found to block translation 
of the incoming Sindbis genomic RNAs, leading to a failure to produce the nsP 
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replication complex.  Altogether, ZAP functions to prevent Sindbis replication and the 
accumulation of viral RNAs within the cytosol of a cell.  Viperin has been less 
extensively studied.  Viperin was first identified as an antiviral molecule that could 
inhibit human cytomegalovirus, possibly through inhibition of viral structural protein 
synthesis (8).  However, Zhang et al. (2007) found that viperin also partially protects 
mice upon Sindbis infections, although the exact mechanism mediating protection 
has not been identified (120).  Therefore, it is unclear exactly how many anti-viral 
ISGs mediate inhibition of alphaviruses or the precise mechanisms that facilitate this 
inhibition.  It is, however, clear that the type I IFN system employs many arms to fully 
combat alphaviruses, making IFN absolutely essential to control these viruses. 
 
Alphavirus modulation on IFN induction 
The Type I IFN response is rapid, robust, and quite effective in inhibiting virus 
replication and spread.  This is highlighted by the fact that mice with a genetic defect 
for the various IFN molecules either rapidly succumb to virus infections or display 
increased viral replication (84, 91, 92, 100, 105).  Furthermore, avirulent viruses that 
are normally cleared in mice with an intact IFN response are more virulent in mice 
without one (105, 113).  Although despite the fact that the IFN response is critical to 
inhibit many different virus infections, a number of viruses seem to persist even in 
the presence of intact IFN response.  Furthermore, evidence suggests that virulent 
viruses, such as Venezuelan Equine Encephalitis virus (VEEV) seem to be more 
resistant to IFN !" activities than their avirulent counterparts (17, 113).  In support of 
this, exogenous priming of the IFN system with IFN !" proteins or with a poly IC 
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inducer, failed to protect mice against a virulent VEEV (26), suggesting a 
mechanism for VEEV to evade IFN responses.  Therefore, given the importance of 
the type I IFN response to control virus replication, it is not surprising that viruses 
have evolved mechanisms to counteract these actions.  These anti-IFN strategies 
can range from non-specific mechanism(s) such as virus induced shutoff of the host 
macromolecular synthesis to specific inhibition of host molecules that directly 
interfere with IFN signaling or the anti-viral ISGs or to masking of the viral ligands to 
evade and IFN response.  Several studies have suggested mechanism(s) for 
alphavirus to actively evade or antagonize the host type I IFN system. 
 A major mechanism for alphaviruses to evade the host type I IFN response is 
thought to be virus mediated shutoff of the host RNA and protein synthesis (15, 24, 
25).  As an alphavirus enters a cell, the viral genome is translated to immediately 
begin the viral replication life cycle.  The replication of the viral genome is fairly 
robust and occurs rapidly after infection.  To aid in this progress, a generalized 
mechanism of host shutoff is employed by the virus.  A few hours post-infection, the 
cellular transcription and translation machinery is redirected to synthesize only the 
viral RNAs and proteins.  The exact mechanism of the host shutoff has not been 
clearly identified although; depending on the alphavirus used, several studies have 
implicated a role for the nonstructural and structural proteins to act within the 
nucleus of a cell.  These studies have led to the general concept that Old World 
alphaviruses (Sindbis and Semliki Forest Virus) mediate transcription shutoff via the 
viral nsP2 protein whereas the New World viruses (Venezuelan equine encephalitis 
and Eastern equine encephalitis viruses) utilize the capsid structural proteins (18, 
27 
20).  In support of these hypotheses, studies have demonstrated that both the nsP2 
and capsid proteins can localize to the nucleus.  Furthermore, mutations that 
disrupts nsP2 and capsid nuclear localization, results in viruses that are unable to 
shutoff synthesis of cellular RNAs (18, 25).  It has been theorized that a generalized 
host shutoff mechanism, in addition to enhancing viral replication, also acts as non-
specific inhibition of the IFN!" responses.  In support of this, alphaviruses that are 
defective for their ability to completely shutoff host cellular synthesis are also robust 
IFN inducers (24).  Therefore, the actions of host shutoff serves two purposes, 1) to 
aid in efficient viral replication and 2) to inhibit IFN !" induction as well as their 
targeted ISGs.  However, recent reports have suggested that in addition to a 
generalized host shutoff, alphaviruses also employ specific IFN antagonists to 
counteract the early IFN!" responses (4, 97, 117).  Therefore, the alphaviruses are 
likely to employ multiple mechanisms that antagonize the IFN response.  
 Many viruses have also evolved to specifically antagonize the IFN response 
by encoding specific molecules that directly inhibit steps within the IFN pathway.  
These include molecules that target the initial IFN induction phase, inhibit molecules 
within the IFN signaling phase (amplification), or to directly inhibit ISG functions.  For 
example, Hepatitis C virus (HCV) encodes a viral protease, NS3/4A, which 
specifically cleaves the IPS-1 signaling molecule from the mitochondrial membranes.  
IPS-1 is absolutely essential for the RIG-I and MDA-5 RNA helicases to induce an 
IFN response.  Therefore, viral mediated cleavage of IPS-1 efficiently downregulates 
IFN " induction upon HCV infection (11, 54).  Ebola viruses, on the other hand, can 
inhibit IFN !" signaling through inhibiting the JAK-STAT pathway.  Ebola viruses 
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encode a viral protein, VP24, which blocks the nuclear accumulation of 
phosphorylated STAT-1 (61, 80).  Therefore, phosphorylated STAT-1 will not bind to 
its ISG promoters, thus effectively preventing a cell from upregulating anti-viral 
genes.  Though alphaviruses were thought to not employ specific mechanisms to 
antagonize IFN induction/signaling, instead relying on the nonspecific shutoff 
mechanisms as described above, recent reports have also identified that 
alphaviruses can mediate specific IFN inhibition independently of its non-specific, 
global shutoff of the host macromolecular syntheses (4, 6, 117).  Simmons et al. 
(2009) demonstrates that Venezuelan equine encephalitis virus (VEEV) can directly 
block STAT-1 phosphorylation, and subsequent nuclear localization, when 
stimulated with IFN-" (97).  Additionally, Yin et al. (2009) also demonstrates s similar 
STAT antagonism with Sindbis viruses (117).  Interestingly, the adult mouse 
neurovirulent Sindbis AR86, as described earlier, also inhibits STAT-1 activation and 
mutation of a single virulence determinant located at nsP1 position 538 (32, 34, 104) 
disrupts this inhibition (Simmons et al., manuscript in progress).  Importantly, these 
studies provide a direct link of a genetic determinant that modulates pathogenesis in 
vivo, to antagonism of STAT activation, suggesting that viral modulation of these 
pathways contributes to viral virulence. 
 In addition to encoding specific molecules to directly antagonize IFN 
signaling, alphaviruses may employ other mechanisms to avoid type I IFN induction 
(12, 28).  Transmission of mosquito-borne viruses requires a successful transition 
from the mosquito into vertebrate hosts by targeting specific cell types that allow the 
virus to efficiently replicate and spread throughout the host.  In order to achieve this, 
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mosquito-borne viruses need to overcome many barriers of the host’s innate 
defense, including the type I IFN response.  Studies have demonstrated that 
mosquito borne viruses target Langerhans cells or myeloid dendritic cells (DCs) that 
are present beneath the skin’s dermal surface (55, 58, 115).  Additive post-
translational modification to the structural proteins, such as glycosylation, enhances 
virus-DC interactions due to glycoprotein interactions with the mannose binding C-
type lectin receptors, such as DC-SIGN, that are present of these cells (9, 45).  
Shabman et al. (2007) discovered, that in addition to promoting DC infections, 
mosquito derived Ross River Virus (RRV) was also a poor IFN inducer (95).  In 
contrast, mammalian derived RRV viruses were robust IFN inducers.  These studies 
further defined that the mammalian derived viruses, added complex N-linked glycans 
to the E2 glycoprotein, whereas mosquito derived viruses added high mannose N-
inked glycans and that the presence of the complex glycans were responsible for 
mediating IFN induction (96).  Further, the presence of the high mannose glycans 
did not actively antagonize the IFN response, as the mosquito-derived viruses were 
unable to suppress the IFN induction mediated by the mammalian virus.  Therefore, 
though it is unclear whether complex N-linked glycans actively promote type I IFN 
induction or whether high mannose N-linked glycans allow the virus to avoid 
recognition, perhaps by retargeting the virus during entry to avoid contact with 
PRRs, these studies do demonstrate that post translational modifications to the virus 
can significantly impact recognition by the host. Therefore, additional studies are 
required to fully evaluate the combined effects of glycan mediated IFN modulation in 
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combination with nonspecific and specific effects on IFN induction in the context of 
alphavirus infection. 
 
DISSERTATION OBJECTIVES 
 
 Alphaviruses are vector borne viruses that can cause massive outbreaks of 
human disease (30, 62, 63, 114).  The viral interactions with the host type I IFN 
system play an important role in determining the outcome of virus infection due to 
the IFN’s potent antiviral activities and its ability to shape the downstream adaptive 
immune response.  However, many viruses have evolved mechanisms to 
antagonize or evade the type I IFN response.  The viral antagonistic mechanisms 
range from non-specific effects such as shutoff of host cellular processes to specific 
inhibition of molecules within the IFN signaling pathway (18, 19, 31, 80).  
Additionally, simple evasion mechanisms of the host IFN system, such as masking 
of viral RNA ligands, are also employed by many viruses to avoid IFN detection (7, 
28).  Therefore, understanding the processes in which a host cell recognizes 
incoming virus to induce type I IFNs, and how viruses subvert these processes, is 
important for improving vaccines and developing therapeutics against them.  
Previous reports from our lab have identified a single determinant within the viral 
nsP1 protein that plays an important role in Sindbis AR86 neurovirulence in adult 
mice (32, 104).  Therefore, the goals of this dissertation are to further understand the 
role of the nsP1 determinant to interact with the host immune system, specifically the 
type I IFN system.  The dissertation objectives are as follows: 
31 
 
 1) Does the Sindbis AR86 nsP1 determinant modulate IFN induction and is it 
     specific to this virus? 
 2) What are the IFN induction pathways that are involved in alphavirus    
     recognition and how does the nsP1 determinant modulate these     
     pathways? 
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ABSTRACT 
Alphaviruses are mosquito-borne viruses that cause serious human and 
animal diseases.  Previous studies demonstrated that a determinant within the 
nsP1/nsP2 cleavage domain of the virulent Sindbis AR86 virus played a key role in 
regulating adult mouse virulence without adversely affecting viral replication.  
Additional characterization of this determinant demonstrated that a virus with the 
attenuating mutation induced more type I IFN production both in vivo and in vitro.  
Interestingly, this phenotype was not specific to the Sindbis AR86 virus, as a similar 
mutation in a distantly related alphavirus, Ross River Virus (RRV), also led to 
enhanced IFN induction.  This effect was independent of virus-induced host shutoff, 
since IRF-3 phosphorylation, which occurs independently of de novo host 
transcription/translation, was induced more robustly in cells infected with the mutant 
viruses.  Altogether, these results demonstrate that critical determinants within the 
nsP1/nsP2 cleavage domain play an important role in regulating alphavirus induced 
IFN responses. 
 
Keywords: Alphaviruses, Sindbis, Ross River, nsP1 mutants, type I IFN induction. 
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INTRODUCTION 
 Alphaviruses are mosquito-borne viruses capable of infecting humans and 
causing various diseases ranging from acute encephalitis to long-term virus-induced 
arthritis.  The Sindbis-group viruses are among the most studied and well 
characterized of the alphaviruses, having been used to identify viral and host factors 
that contribute to virus-induced disease in mice (27, 35, 42).  The majority of the 
Sindbis virus strains are avirulent in adult mice, however, there are a few exceptions, 
including the neurovirulent neuroadapted Sindbis virus (NSV) (44) and AR86 strains 
(17, 40).  Genetic studies have mapped virulence determinants of these 
neurovirulent viruses to both the structural and nonstructural proteins.  Detailed 
genetic mapping studies using chimeric viruses that encode regions of the adult 
mouse virulent AR86 and the closely related avirulent GirdwoodS.A identified four 
major neurovirulence determinants in the AR86 genome including, a Threonine at 
nsP1 position 538, an 18-amino acid deletion at nsP3 386, a Cysteine at nsP3 
position 537, and a Serine at E2 position 243 (42).  While all four determinants were 
found to be essential for adult mouse virulence, the determinant within nsP1 was 
found to be critical; as a single coding change of this determinant from a Thr to Ile 
severely attenuated the virus, while introduction of a Thr at this position into non-
virulent viruses partially rescued virulence (17).  Currently, the exact mechanism by 
which this determinant affects viral virulence is not understood.  
The alphavirus nonstructural proteins form the viral replication complex that 
mediates cytoplasmic viral RNA synthesis within infected cells.  Nonstructural 
polyprotein processing is intimately linked to viral RNA synthesis (21, 38).  Upon 
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viral entry, the virion-associated RNA is immediately translated to form the 
replication complex consisting of the nonstructural precursor, nsP123, and nsP4, 
which together mediate negative strand RNA synthesis (41).  Later in the course of 
infection, the polyprotein precursor nsP123 is further processed by nsP2 to produce 
mature nsP1, nsP2, and nsP3.  The mature nonstructural proteins, together with 
nsP4, form the replication complex to synthesize full length genomic RNA.  The 
mature nsPs also bind to an internal subgenomic promoter to synthesize smaller 
subgenomic RNAs that encode the viral structural proteins.  Previous studies using 
mutants that lack the ability to efficiently process the nonstructural polyprotein 
precursor nsP123 showed dysregulation of viral RNA synthesis (21).  Interestingly, 
the wild type AR86 Thr to Ile change at nsP1 position 538, is located in the P3 
position of the conserved nsP1/2 cleavage recognition domain (38).  The presence 
of an attenuating Ile at this position results in increased kinetics of nonstructural 
polyprotein processing as well as earlier induction of 26S subgenomic RNA 
synthesis.  Furthermore, this mutation did not affect full length negative or positive 
strand RNA synthesis, though it did result in increased virus production (18).  
Whether differential nonstructural protein processing or the increased 26S RNA is 
important for the attenuated phenotype of this virus in vivo has yet to be determined. 
In addition to mediating viral replication, the nonstructural proteins interact 
with host factors to alter environmental conditions that favor viral replication (10, 26).  
The nonstructural proteins of Old World alphaviruses, such as Sindbis and Semliki 
Forest virus, have been shown to mediate shutoff of host transcription and 
translation (11).  While the exact mechanism of virus-mediated host shutoff is not 
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completely understood, it has been proposed that mature nsP2 is required (14, 15).  
Alphaviruses are thought to down regulate host mRNA and protein synthesis in 
order to limit competition for the cellular machinery to maximize viral replication while 
simultaneously limiting induction of type I IFN and related IFN stimulated genes 
(ISGs).   
Sindbis viruses are highly sensitive to the effects of type I IFN (9).  Type I IFN 
receptor deficient mice exhibited enhanced susceptibility to Sindbis virus marked by 
increased virulence, broadened tissue tropism, and uncontrolled virus replication 
(34), demonstrating that type I IFN plays an important role in controlling Sindbis virus 
infection.  Therefore, it is likely that Sindbis virus utilizes several mechanisms to limit 
and/or suppress type I IFN induction.  One likely mechanism involves generalized 
suppression of host macromolecular synthesis.  In support of this, Sindbis virus 
mutants that are defective for host shutoff are more potent inducers of the type I IFN 
response (14, 15).  However, host shutoff independent mechanisms likely exist, as a 
mutation in the nsP2 protein of Semliki Forest Virus, a related alphavirus, affects 
type I IFN induction independently of generalized host shutoff (6). 
In this study, we demonstrate an important role for a determinant at the P3 
cleavage position between nsP1 and nsP2 in regulating type I IFN induction.  
Mutation of this position in two distantly related alphaviruses, the AR86 strain of 
Sindbis and Ross River Virus, resulted in enhanced type I IFN induction and IRF-3 
activation in comparison to the wild type viruses.  Furthermore, the P3 mutation had 
little effect on kinetics of virus mediated host transcription and translation shutoff.  
Taken together, these results suggest that the P3 determinant, which regulates 
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AR86 virulence, plays a major role in regulating type I IFN induction that is 
independent of virus mediated host shutoff. 
 
RESULTS 
An attenuating Isoleucine mutation at nsP1 position 538 (T538I) in the Sindbis 
virus AR86 backbone leads to increased type I IFN induction in vivo and in 
vitro.   
 A virulence determinant located within the nsP1/nsP2 cleavage domain 
(nsP1 538) of the Sindbis virus, AR86, regulates viral nonstructural polyprotein 
processing and subgenomic RNA synthesis (18).  Given that the presence of the 
attenuating Ile mutation led to earlier induction of viral 26S RNA synthesis, which 
could alter type I IFN induction, we assessed whether the attenuated mutant virus 
exhibited any differences in type I IFN induction from that of the wild type virus both 
in vivo and in vitro.  To evaluate whether the viruses exhibited differential IFN 
induction in vivo, six-week old CD-1 mice were mock infected or infected with the 
wild type AR86 (previously referenced as s300 (42)) or mutant T538I (nsP1 538 Ile 
previously referenced as s340) viruses by the intracranial route (i.c.) and bled 
between 9 and 18 hours post infection.  Serum type I interferon responses were 
measured using an interferon bioassay on L929 cells.  As shown in figure 2.1A, 
serum from mice infected with the mutant T538I virus exhibited robust type I 
interferon levels compared to mice infected with the wild type AR86 virus at both 12 
and 18 hours post infection as detectable by bioassay.  Similar results were 
observed in C57BL/6 mice (data not shown).  Importantly, wild type AR86 did not 
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induce detectable type I interferon up to 48 hours post-infection (data not shown), 
indicating that the wild type virus was not simply delayed in the induction of type I 
interferon.  To further assess whether the mutant virus was a more potent inducer of 
type I IFN, L929 cells were infected with either the wild type AR86 virus or the T538I 
mutant and type I IFN levels in the supernatant were evaluated.  As shown in figure 
2.1B, similar to the in vivo results, the attenuated mutant was a more potent inducer 
of type I IFN than the wild type virus.  These results were not restricted to L929 cells, 
since the mutant virus was also a more potent IFN inducer in human cell lines such 
as A549 cells (data not shown).  Overall, these results suggest that the determinant 
at nsP1 position 538 plays a major role in regulating type I IFN induction by the 
virus.   
Previous studies with Sindbis viruses have suggested that virus-mediated 
host cellular macromolecular shutoff is linked to IFN induction.  Some Sindbis virus 
mutants that are potent IFN inducers are also defective in their ability to shutoff host 
RNA synthesis (14), raising the possibility that the nsP1 mutation in AR86 affected 
type I IFN induction through effects on host macromolecular synthesis.  Therefore, 
we assessed the kinetics of transcriptional and translational shutoff between the wild 
type and mutant AR86 viruses.  These studies utilized L929 cells, since the T538I 
mutant exhibited enhanced type I IFN induction in this cell type (figure 2.1B).  
Unfortunately, we were unable to achieve 100% infection at low MOIs.  Therefore, 
the MOI was increased to 50 to increase the percent of infected cells and to limit the 
confounding effect of nonproductively infected cells in the culture continuing 
transcription/translation and complicating the analysis of virus-induced shutoff of 
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these processes.  As shown in figure 2.2A, both the wild type and the mutant viruses 
exhibited similar kinetics of host transcription shutoff at 5 hours post-infection as 
observed by the loss of host mRNA, 28S rRNA, and 18S rRNA.  By 8hpi, both 
viruses have efficiently turned off host transcription.  Interestingly, in Neuro2A cells, 
the wild type Sindbis AR86 virus exhibited less efficient shutoff of host mRNA, 28S 
rRNA and 18S rRNA as compared to the mutant T538I virus suggesting that the 
T538I mutant may actually shutoff transcription more efficiently than the wild type 
virus (data not shown).  Additionally, the wild type and mutant Sindbis viruses were 
equally efficient at inhibiting host protein translation (figures 2.2B and 2.2C).  As 
early as 4 hours post-infection, both viruses exhibit greater than 25% shutoff of host 
protein synthesis and by 8 hours post-infection greater than 75% of host protein 
synthesis shutoff was observed (figure 2.2C).  Most importantly, when comparing the 
!-actin band, the mutant T538I virus displayed similar kinetics of host protein shutoff 
as compared to wild type AR86 virus (figure 2.2B).  Similar observations were also 
made in Neuro2A and BHK-21 cells (data not shown).  These results suggest that 
the Sindbis virus mutant induced enhanced type I IFN production in the absence of a 
detectable defect in generalized host cell shutoff.  
 
Mutation of the nsP1 determinant in Ross River Virus results in enhanced type 
I IFN induction by the mutant virus.   
To determine if the effect of the amino acid within the nsP1/nsP2 cleavage 
domain on type I IFN induction was specific to AR86, similar mutations were 
introduced in the distantly related alphavirus, Ross River Virus (RRV) (figure 2.3A).  
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RRV encodes an Alanine codon at the same position within the nsP1/2 cleavage site 
and we examined whether substitution with an Isoleucine (A532I) or Valine (A532V) 
would result in a viable virus with similar effects on type I IFN induction as seen with 
the Sindbis T538I mutant (figure 2.1).  Substitution of an Isoleucine in RRV resulted 
in a significantly attenuated virus that grew poorly in BHK-21 cells (data not shown).  
In contrast, substitution of an Alanine to Valine resulted in a viable virus that grew to 
levels comparable to wild type RRV, though the Valine mutant displayed a smaller 
plaque phenotype on BHK-21 cells (data not shown).  Furthermore, the RRV A532V 
mutant had a similar RNA specific infectivity and particle to PFU ratio to those 
observed with the wild type virus (data not shown).  In both single (figure 2.3B) and 
multi-step (figure 2.3C) growth curves in BHK-21 cells, the A532V mutant exhibited a 
significant and reproducible reduction in viral yield at intermediate times (7-16hpi), 
although the endpoint yield was identical to wild type RRV.  Therefore, the A532V 
mutant is viable, though it may exhibit a slight replication defect as compared to the 
wild type virus.   
In order to assess the impact of the A532V mutation on type I IFN induction, 
L929 cells were infected with either the wild type RRV or the RRV A532V mutant, 
and type I IFN induction in the supernatant was measured by bioassay.  As shown in 
figure 2.4A, the A532V mutant exhibited enhanced IFN induction (~90 fold) in 
comparison to wild type RRV at 24 hours post-infection.  Similar results were found 
by qRT-PCR analysis for IFN-beta mRNA transcripts at early times post-infection 
(figure 2.4B and 2.4C).  Altogether, these data, along with the earlier findings with 
the Sindbis AR86 viruses, highlight the importance of the determinant within the 
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nsP1/nsP2 cleavage site in modulating type I IFN responses by at least two 
alphaviruses.   
  
The A532V mutation affects type I IFN induction.   
Recent work from our group and others has demonstrated that another 
alphavirus, Venezuelan equine encephalitis virus (VEEV) can antagonize STAT1 
activation following treatment with type I IFN (39, 46).  Although, to date we have 
found no evidence that wild type RRV can antagonize STAT1 activation (Simmons 
and Heise, unpublished), we were interested in determining whether the A532V 
mutation affected the early induction of type I IFN or the amplification phase of the 
type I IFN response, which is dependent upon type I IFN signaling and STAT1 
activation.  Thus, we compared the wild type and mutant A532V RRV viruses for 
their ability to induce type I IFN in primary MEFs derived from wild type mice or mice 
deficient in the type I IFN "! receptor (IFNR), which are therefore unable to mount 
an amplified type I IFN response.  As shown in figure 2.5A, similar to the results from 
the L929 cells, the mutant virus was a more potent type I IFN inducer than wild type 
RRV in wild type MEFs.  In IFNR deficient MEFs, the overall type I IFN induction 
was reduced compared to wild type cells, however the mutant virus still induced 
significantly more type I IFN than the wild type virus (figure 2.5B).  Therefore, though 
we cannot rule out an effect of the A532V mutation on type I IFN signaling and 
subsequent amplification of the IFN response, these results strongly suggest that the 
nsP1 mutation does have an effect on the inductive phase of the type I IFN 
response.    
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The RRV A532V exhibits a mild defect in virus-induced shutoff of host RNA 
and protein synthesis.   
The Sindbis T538I mutant exhibited little defect in virus-induced shutoff, 
therefore we determined whether this was also the case with the RRV A532V 
mutant.  RRV or A532V were evaluated for their ability to shut off host protein and 
RNA synthesis in a manner similar to that described above for AR86.  L929 cells 
were infected with the RRV viruses at an MOI of 50 to enhance the percentage of 
infected cells in the culture.  At this MOI, the percentage of infected cells was greater 
than 80% for both viruses as demonstrated by an Immunofluorescent Assay (IFA) 
(data not shown).  Importantly, the RRV A532V mutant still induced an enhanced 
IFN response compared to the wild type virus at this MOI (figure 2.6D).  Both wild 
type RRV and the mutant A532V viruses inhibited cellular RNA transcription as early 
as 5 hours post-infection as indicated by the decline in 18S rRNAs as compared to 
mock infected cells (figure 2.6A).  By 8 hours post-infection, both viruses efficiently 
turned off 18S rRNA synthesis.  Similar results were also obtained in BHK cells 
though interestingly, in BHK cells, the A532V mutant displayed a slight delay in 
transcriptional shutoff at early times post-infection compared to the wild type RRV 
virus (data not shown).  Therefore, though the A532V mutant is capable of shutting 
off host RNA synthesis we cannot rule out the possibility that the A532V mutant virus 
may be slightly delayed in its ability to turn off cellular RNA synthesis.  Analysis of 
virus induced inhibition of host protein synthesis (figure 2.6B) demonstrated that 
both viruses inhibit cellular protein synthesis in L929 cells with similar kinetics as 
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indicated by the loss of the !-actin band (figure 2.6C).  Similarly to the transcriptional 
shutoff data, in BHK cells, the A532V mutant was slightly delayed in inhibiting 
protein translation in comparison to the wild type virus (data not shown).  Therefore, 
though the mutant RRV is ultimately able to shut off host cell RNA and protein 
synthesis, based on these results, we cannot rule out the possibility that a slight 
defect in shutoff might contribute to the enhanced type I IFN induction by the A532V 
RRV mutant.  
  
The A532V mutant virus is a strong inducer of IRF-3 phosphorylation than the 
wild type virus. 
The results with the Sindbis T538I mutant suggest that host shutoff defects do 
not contribute to the enhanced type I IFN induction by the mutant virus.  
Furthermore, though we could not detect a defect in the RRV A532V mutant’s ability 
to shutoff host transcription or translation in L929 cells, the delayed kinetics of 
shutoff by the A532V mutant in BHK cells left open the possibility of shutoff 
dependent effects for the RRV mutant.  Therefore, to more clearly address this 
issue, we assessed the RRV viruses for their ability to activate IRF-3, a step that is 
independent of de novo host RNA and protein synthesis and therefore not 
susceptible to shutoff mediated effects (32).  IRF-3 is an essential transcription 
factor that is immediately activated by several pathogen-associated molecular 
pattern receptors to induce early transcription of IFN-! and IFN-" genes.  Activation 
is initiated upon IRF-3 phosphorylation resulting in protein dimerization and nuclear 
translocation.  Therefore, we assessed whether the mutant RRV virus exhibited 
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differential IRF-3 activation compared to the wild type RRV in L929 cells, which 
exhibited high levels of type I IFN induction by the RRV A532V mutant (figure 2.4A).  
L929 cells were transfected with poly IC as a positive control (16), which resulted in  
robust IRF-3 phosphorylation as indicated by the shift in the IRF-3 protein band in 
comparison to the mock treated cells (figure 2.7A).  Additionally, phosphatase 
treatment of cell lysates confirmed that the upper band was indeed a phosphorylated 
protein (data not shown).  Analysis of the virally infected cells demonstrated that the 
RRV A532V mutant virus induced IRF-3 phosphorylation at 10 hours post-infection; 
however, the wild type RRV virus did not display IRF-3 phosphorylation until as late 
as 12 hours post-infection.  Also, there was substantially more IRF-3 
phosphorylation at 12 hours post-infection in cells infected with the A532V mutant 
virus (figure 2.7B), consistent with our previous data that the RRV A532V mutant 
induces more IFN than wild type RRV.  Similar to the results with RRV, the AR86 
T538I mutant induced faster and more robust IRF-3 activation than the wild type 
virus in HEC-1B cells, human endometrial carcinoma cells, that have been well 
characterized in IRF-3 activation studies and do not respond to IFN treatment (8, 
43)(data not shown).  Altogether, these results suggest that both the AR86 and RRV 
mutants affect IFN induction through a mechanism that is independent of virus-
induced host shutoff.  However, given that the RRV A532V mutant did exhibit 
delayed shutoff kinetics in BHK cells, we cannot rule out a synergistic role for shutoff 
dependent and independent effects in enhancing type I IFN induction by the RRV 
A532V mutant.  
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DISCUSSION 
Type I interferon is an essential component of the host response to viral 
infection, because it directly activates antiviral systems and modulates antiviral 
activities of other components of the host innate and adaptive immune systems.  
However, a number of viruses have evolved mechanisms to antagonize or evade 
type I IFN induction.  These mechanisms range from nonspecific effects, such as 
rapid shutoff of host cell macromolecular synthesis (1, 14), masking viral RNA from 
host cell sensory proteins (7, 25), to specific inhibition of host cell dsRNA sensors or 
signaling molecules that link these sensor molecules to transcription factors that 
regulate type I interferon transcription (4, 5, 22, 23).  Studies with Sindbis virus 
suggest that host cell shutoff plays a major role in regulating viral type I interferon 
induction (14), though studies with Semliki Forest virus (SFV) also indicate that 
alphaviruses can modulate type I IFN responses independently of host shutoff (6).  
In this report, we present evidence that an attenuating mutation at nsP1 position 538 
(T538I) in the neurovirulent strain of Sindbis virus, AR86, modulates type I interferon 
induction without affecting this virus’s ability to shut off host cell macromolecular 
synthesis.  Additionally, this determinant has been shown to play a key role in 
regulating viral neurovirulence (17), and it is likely that the enhanced type I IFN 
induction by the nsP1 538 mutant virus in vivo (figure 2.1A) is at least partially 
responsible for its attenuating effect on AR86.  Furthermore, the importance of this 
determinant in regulating type I IFN induction by alphaviruses is underscored by our 
finding that an analogous mutation in another alphavirus, Ross River Virus, exerts a 
similar effect on type I IFN induction (figure 2.4 and 2.5). 
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 Using a genetically related Sindbis virus, Gorchakov et al. (2005) 
demonstrated that viruses with mutations resulting in defects in host translation or 
transcription shutoff induced more type I interferon (14).  However, we found either 
no difference or a very mild defect in host shutoff with the mutant Sindbis and RRV 
viruses, as well as differences in the kinetics of virus induced IRF-3 activation, which 
is independent of host shutoff.  This finding strongly suggests that these viruses can 
affect type I IFN induction independently of effects on host shutoff.  It is also 
important to note that previous work with an SFV nsP mutant, which also 
demonstrated a role for the nonstructural proteins in modulating type I IFN induction 
independently of host shutoff effects, did not observe a differential effect on IRF-3 
activation (6), which raises the possibility that the determinants in our AR86 and 
RRV mutants may affect interferon induction through different mechanisms than 
those observed with SFV.  Furthermore, previous work from our lab and others have 
demonstrated a role for VEE to inhibit STAT-1 activation (39, 46), a necessary step 
in the IFN signaling pathway to amplify the type I IFN response indicating that these 
viruses may employ additional mechanisms to antagonize this pathway.  However, 
our analysis in IFN "! Receptor deficient MEFS, coupled with preliminary data that 
wild type RRV does not inhibit STAT-1 activation, further suggests that our 
determinant is affecting the initial IFN induction step. 
 The nsP1 virulence determinant described here might affect type I IFN 
induction through several different mechanisms.  First, the nsP1 mutant may induce 
more type I IFN by producing earlier and/or increased quantities of a viral ligand, for 
efficient recognition by the host sensors.  Previous studies examining very early 
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times post-infection demonstrated that the AR86 mutant virus initiated 26S RNA 
synthesis more quickly than the wild type virus, though both viruses exhibited 
equivalent levels of 26S RNA synthesis by 4-6 hours post-infection (18).  Although, 
we did not observe this kinetic difference in our L929 RNA labeling assays, this likely 
reflects the time-points analyzed in the current studies.  Our earlier results raise the 
possibility that early or more abundant 26S RNA synthesis by the mutant virus might 
be linked to the difference in type I IFN induction.  Preliminary analysis indicates that 
the RRV mutant may also produce more viral RNA than the wild type virus (data not 
shown).  In this model, the wild type virus could delay 26S promoter induction until 
later times when virus-induced host shutoff efficiently antagonizes type I interferon 
induction.  The attenuating mutation at nsP1, however, up-regulates 26S RNA 
synthesis prior to the time of effective virus-induced shutoff (18).  This model 
suggests that the subgenomic RNA may be a potential target for host cell sensors, 
however; this does not rule out a role for multiple viral RNA species, such as the full 
length positive or negative sense RNA, or dsRNA complexes to activate IFN 
induction.  Further investigations will be required to address the exact viral ligand 
required as well as the pathway that is mediating this response and whether this 
mechanism holds true for both viruses.  Second, the nsP1 mutant may induce more 
type I IFN by altering the structure of one or more viral RNAs and thereby producing 
a stronger ligand.  Gitlin et al. (2006) has reported that RIG-I plays an important role 
in responding to Sindbis virus infection (13), while PKR has also been shown to 
contribute to type I IFN induction during flavivirus infection (12).  Both RIG-I and 
PKR interact with 5-’triphosphates on uncapped RNAs (19, 30, 31), though both 
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proteins can also recognize other RNA ligands (29, 36).  Both nsP1 and nsP2 
proteins are involved in capping viral RNAs and though the C-terminus of nsP1 has 
not been implicated in capping activity, it is possible that the determinant at nsP1 is 
altering the efficiency of capping viral genomic or subgenomic RNAs (2, 3, 19, 24, 
33, 45).  In this model, the nsP1 mutants are providing the host sensor, RIG-I, with 
viral ligands that contain free 5’-triphosphates that lead to stronger IFN-! induction.  
Finally, though there is no direct evidence to suggest that the wild type and T538I 
mutant Sindbis AR86 viruses or RRV and the A532V RRV mutant differ in their 
ability to actively suppress type I IFN induction, it is possible that the mutation is 
modulating type I IFN induction through different mechanisms in the context of each 
virus.  Regardless of the ultimate mechanism responsible for the differential type I 
IFN induction phenotype, these results further support the idea that determinants in 
the viral nonstructural region of alphaviruses play a major role in regulating type I 
IFN induction, with a concomitant impact on viral virulence. 
In summary, we have demonstrated that wild type AR86 virus was a poor 
inducer of type I interferon, while the mutant T538I virus containing an attenuating Ile 
codon at nsP1 position 538 induced a robust type I interferon response in vitro and 
in vivo.  An analogous determinant exhibited a similar effect in another, distantly 
related alphavirus (RRV), suggesting that this determinant plays an important role in 
regulating type I IFN induction by multiple alphaviruses.  The altered interferon 
induction was independent of virus-induced host translation or transcription shutoff, 
suggesting that the determinant within the nsP1/nsP2 cleavage site acts through a 
more specific mechanism to modulate the host type I interferon response.   
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MATERIALS AND METHODS:  
Viruses and Cell Culture:  The AR86 molecular clones pS300 (wild type nsP1 538 
Thr) and pS340 (mutant nsP1 538 Ile) were described previously (17).  The wild type 
Ross River Virus molecular clone, pRR64 (20), was generously provided by Dr. 
Richard Kuhn (Purdue University).  The Ross River Virus mutant, pRR64-A532V, 
was generated by introducing a single nucleotide change (thymine to guanine) at 
nucleotide position 1670, by PCR mutagenesis resulting in a single codon change 
from an Alanine (wild type) to Valine (A532V) at nsP1 position 532. 
Viral stocks were generated by in vitro transcription as previously described 
(18, 28).  Briefly, cDNA plasmids were linearized and used as templates for full 
length RNA transcripts generated by SP6-specific mMessage mMachine in vitro 
transcription kits (Ambion).  Transcripts were electroporated into BHK-21 cells using 
a Bio-Rad electroporator.  Supernatants were harvested 24 hours later, centrifuged 
for 20 min at 3,000 RPM, and frozen in 0.5 ml aliquots.  Alternatively, electroporated 
supernatants were pelleted through a 20% (w/v) sucrose/phosphate buffered saline 
(PBS) cushion at 72,000 # g by ultracentrifugation (four hours) to concentrate viral 
stocks.  The pelleted viruses were resuspended in PBS and 0.1ml aliquots were 
frozen at -80°C.  Viral titers were determined by standard plaque assays on BHK-21 
cells.   
BHK-21 cells were maintained in alpha minimum essential medium (Gibco) 
supplemented with 10% bovine calf serum (BioWhittaker), 10% tryptose phosphate 
broth, and 0.29 mg/ml of L-glutamine.  L929 mouse fibroblast cells were maintained 
in alpha minimum essential medium (Gibco) supplemented with 10% bovine calf 
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serum, 10% tryptose phosphate broth, and 0.29 mg/ml of L-glutamine.  Neuro2A 
mouse neuroblastoma cells (N2A) were grown in MEM containing nonessential 
amino acids and 10% fetal bovine serum (HyClone).  HEC-1B cells (ATCC) were 
grown in MEM containing 10% fetal bovine serum, 0.29 mg of L-glutamine per ml, 
and penicillin/streptomycin.  Primary Mouse Embryonic Fibroblast (MEFS) cells were 
generated from 13-15 day old Sv/129 wild type or IFN "! receptor deficient (IFNR-/-) 
embryos and maintained in DMEM/F12 media containing 10% Fetal Bovine Serum, 
10% tryptose phosphate broth, 0.29 mg/ml of L-glutamine, and 50ug/ml of 
gentamicin (Gibco).   
 
Animal studies:  Specific pathogen-free six-week old female CD-1 mice were 
obtained from Charles River Breeding Laboratories (Raleigh, NC), while C57Bl/6J 
mice were bred in house.  Animal housing and care were in accordance with all 
University of North Carolina at Chapel Hill Institutional Animal Care and Use 
Committee guidelines.  In all studies, six- to eight-week-old mice (groups of 3 to 6 
animals/study) were anesthetized with Ketamine supplemented with Xylazine 
(Barber Med.) prior to intracranial (i.c.) inoculation with a standard dose of 103 PFU 
of virus in diluent [phosphate-buffered saline (PBS, pH 7.4)], supplemented with 1% 
donor calf serum (DCS, Gibco)).  Mock infected mice received diluent alone.  At the 
indicated timepoints, mice were bled from the tail vein and sera were frozen at -80°C 
until analyzed for type I interferon by bioassay (see below).  
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Type I IFN bioassays:  Total amounts of type I IFN were measured by using an 
interferon bioassay as previously described (37).  Briefly, L929 cells were seeded in 
96 well plates.  Samples, including the standards, were acidified to a pH $ 2.0 for 24 
hours, then neutralized to pH of 7.4, UV treated for 10 minutes to inactivate residual 
virus, and added to cells in a titration of serial two-fold dilutions.  After overnight 
incubation, 50ul of a 4x106 PFU/ml stock of encephalomyocarditis virus (EMCV) was 
added to each well.  Twenty-four hours post-infection, cell viability was determined 
using 3-(4, 5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, Sigma) 
assay, and the absorbance was read on a microplate reader at 570nm.  The IFN in 
each sample was compared to an IFN standard (from Chemicon or R&D Systems 
that has been normalized to the National Institutes of Health reference IFN) present 
in each plate and converted to international units (IU/ml). 
 
Quantitative real-time PCR analysis:  L929 cells were seeded in 6-well dishes and 
either mock infected or infected with RRV wild type and A532V RRV mutant viruses 
at an MOI of 5.  At the indicated time points, total RNA was isolated using the Trizol 
(Invitrogen) and the PureLink RNA Mini Kit protocol (Invitrogen).  Total RNA was 
reverse transcribed using random primers and SuperScript III Reverse Transcriptase 
Kit (Invitrogen).  cDNAs were then probed for IFN-beta and 18S rRNA message 
using TaqMan real-time PCR with primer probe sets (Applied Biosystems) and 
analyzed on the Prism 7000 machine (Applied Biosystems). 
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Analysis of Protein Synthesis:  L929, BHK-21, or Neuro2A cells were either mock 
infected or infected with the Sindbis AR86 or RRV viruses at an MOI of 50 and 10 
(BHK and N2A).   At various times post-infection, the media was removed and cells 
were starved with Minimum Essential Eagle Medium with Earle’s salts lacking 
methionine and cysteine (MP biomedicals) for 1 hour at 37ºC.  The starvation media 
was then replaced with media supplemented with 33µCi of 35S-methionine and 35S-
cysteine (Amersham Pro-mix) and incubated at 37ºC for one hour.  Following each 
labeling period, cells were lysed in NP-40 Lysis buffer containing protease inhibitors 
(Roche).  Equal cell lysates were analyzed on a 10% sodium dodecyl sulphate 
polyacrylamide gel (SDS-PAGE).  Gels were fixed in buffer containing 10% acetic 
acid and 40% methanol.  The gels were then dried, exposed to a phosphoimaging 
screen, and scanned using a Storm Phosphoimager (GE Healthcare).  !-actin bands 
were quantified using ImageQuant software (GE Healthcare), and samples are 
represented as comparison to mock infected cells. 
 
Analysis of Host RNA Synthesis:  L929, BHK, or Neuro2A cells were either mock 
infected or infected with the Sindbis AR86 or the RRV viruses at an MOI of 50 and 
10 (BHK and N2A).  After 1 hour incubation, 2ml of media were added back to cells.  
At various times post-infection (2, 5, 8, and 16hpi), the media were replaced with 
media supplemented with 20uCi/ml [3H]-uridine (in the presence or absence of 
actinomycin D (1ug/ml)).  The cells were labeled for a total of 3 hours, then washed 
with 1XPBS and lysed in Trizol (Invitrogen).  RNA was extracted and equal volumes 
were denatured in glyoxal and dimethyl sulfoxide (DMSO) for 1 hour at 50ºC.  The 
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RNA was analyzed on a 0.8% agarose NaPO4 gel.  The agarose gel was washed 
twice in methanol followed by overnight incubation in 2.5% 2, 5-diphenyloxazole 
(PPO) in methanol.  The gel was washed three times in water to precipitate the 
PPO, dried, and exposed to film. 
 
SDS-PAGE and Western Blot Analysis:  Protein extracts were resolved on 10% 
SDS-PAGE followed by transfer to a PVDF membrane.  Anti-IRF-3 C-20 antibody 
(Santa Cruz) was used for detection of phosphorylated IRF-3 in L929 cells.  For re-
probing of the membranes, anti-!-actin (Sigma) antibodies were used.  Membranes 
were washed and incubated in the appropriate anti-rabbit and anti-goat secondary 
antibodies. 
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FIGURE 2.1 
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Figure 2.1. The mutant SIN T538I virus induces more type I interferon.  A) 
Groups of six-week old (n=3) CD-1 mice were infected with diluent alone, wild type 
Sindbis AR86, or Sindbis T538I mutant at 1x103 pfu via the intracranial (i.c.) route.  
Serum was harvested at the indicated time points (hours) and diluted (1:10) into 
media.  B) L929 cells were either mock infected or infected with wild type AR86 or 
T538I mutant at an MOI of 5.0 and supernatants were harvested at 18 hours post-
infection.  Serum and supernatants were subjected to an interferon bioassay on 
L929 cells.  Each bar represents the average of triplicate samples and the p values 
were determined by ANOVA statistical analysis.  Error bars represent the standard 
error of the mean.  The limit of detection in each bioassay was 31IU/ml.  
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FIGURE 2.2 
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Figure 2.2: The Sindbis T538I mutant virus shuts off host RNA transcription 
and protein translation with similar kinetics to the wild type AR86.  L929 cells 
were mock infected (M) or infected with wild type Sindbis AR86 (T) or mutant T538I 
(I) at an MOI of 50.  A) To analyze host RNA synthesis, at various times post-
infection (2, 5, 8, and 16 hours), the media was replaced with media containing 
20µCi/ml of 3H-Uridine and cells were labeled for a total of 3 hours.  Total RNA was 
harvested and analyzed by agarose gel electrophoresis as previously described.  B) 
To analyze host protein synthesis, L929 cells were labeled with 35S Met/Cys for 1 
hour at the hours indicated and cell lysates (in duplicates) were analyzed by SDS-
PAGE.  C) Residual host cell protein synthesis in figure 2.2B was evaluated by 
measuring the amount of radioactivity detected in the protein band corresponding to 
actin (as marked by the arrow) and normalized to the amount of radioactivity 
detected in the same protein band in mock infected cells (AR86-%, T538I-&).  The 
data shown are representative of two independent experiments. 
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FIGURE 2.3 
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Figure 2.3.  Characterizations of the RRV A532V mutant virus.  A) Schematic 
diagram of the single amino acid substitutions in the Sindbis AR86 (T538I) and Ross 
River Virus (A532I and A532V) mutants.  B) Single step growth curve.  BHK cells 
were infected at an MOI of 5 with either RRV (') or A532V (() viruses.  
Supernatants at 1, 4, 7, 10, 13, and 25hpi were analyzed by plaque assay.  C) Multi-
step growth curve.  BHK-21 cells were infected at an MOI of 0.01 with either RRV 
(') or A532V (() viruses.  Supernatants at 4, 7, 10, 13, 16, and 25hpi were analyzed 
by plaque assays. Each data point represents the average of triplicate samples and 
significance was determined by a 2-factor ANOVA statistical analysis (*p<0.05, 
**p<0.01).  Error bars represent the standard error of the mean. 
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FIGURE 2.4 
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Figure 2.4.  The RRV A532V mutant virus induces more type I IFN than the wild 
type.  L929 cells were infected with RRV and A532V viruses at an MOI of 5.  A) 
Type I IFN bioassays were performed on the supernatants harvested at 24 hpi.  The 
limit of detection for the bioassay is 7 IU/ml.  B) and C) Total RNA was extracted at 6 
hpi (B) or 12 hpi (C) and analyzed by quantitative real time PCR (Applied 
Biosystems) for IFN-beta message transcripts.  The data are represented as the fold 
induction over Mock infected cells and have been normalized to 18S rRNA.  Each 
bar above represents the average of triplicate samples and the p values were 
determined by ANOVA statistical analysis.  Error bars represent the standard error 
of the mean. 
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FIGURE 2.5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.5.  The RRV mutant virus induces more IFN than the wild type RRV in 
the absence of the Type I IFN !" Receptor.  A) Sv/129 MEFS and B) Sv/129 
IFNR-/- MEFS were infected with RRV and A532V viruses at an MOI of 5.  Type I 
IFN bioassays were performed on the supernatants harvested at 24 hpi.  Each bar 
represents the average of triplicate samples and the p values were determined by 
ANOVA statistical analysis.  Error bars represent the standard error of the mean and 
the limit of detection for each bioassay is 61 IU/ml). 
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FIGURE 2.6 
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Figure 2.6.  Characterization of virus-induced shutoff by the RRV A532V 
mutant.  L929 cells were either mock infected (M) or infected at an MOI of 50 with 
RRV (R) or A532V (V).  A) At various times post-infection (2, 5, 8, and 16 hrs), cells 
were labeled with 20µCi/ml of 3H-Uridine (as previously described) for analysis of 
host RNA synthesis.  B) L929 cells were labeled with 35S Met/Cys at the indicated 
times post-infection for 1 hour to monitor host protein synthesis.  Total cell lysates 
(duplicates) were analyzed by SDS-PAGE as described in the materials and 
methods.  C) The kinetics of cellular !-actin protein synthesis was evaluated by 
measuring the amount of radioactivity detected by densitometry in the !-actin protein 
band in the infected cells and normalized to the mock infected cells at 24hpi.  D) 
L929 cells were either mock infected or infected with RRV or A532V mutant viruses 
at an MOI (50).  Supernatants at 24hpi were analyzed for IFN by bioassay as 
previously described.  The limit of detection in this assay is 2 IU/ml and each bar 
represents the average of triplicate samples.  The p-values were determined by 
ANOVA statistical analysis and error bars represent the standard error of the mean 
 
 
 
 
 
 
 
 
85 
FIGURE 2.7 
 
Figure 2.7.  The RRV A532V mutant robustly induces IRF-3 phosphorylation 
compared to wild type virus.  A) L929 cells were either mock infected, infected 
with RRV and A532V viruses at an MOI of 5, or transfected with 1ug of poly I:C with 
Lipofectamine 2000 (Invitrogen).  Cells were lysed at the indicated hours in NP40 
lysis buffers containing protease and phosphatase inhibitors.  20ug of total protein 
was analyzed by SDS-PAGE and probed with an anti-IRF-3 antibody (Santa Cruz, 
C-20) for phosphorylated murine IRF-3 (p-IRF-3).  The membranes were then re-
probed with an anti-!-actin antibody (Sigma).  B) The phosphorylated IRF-3 bands in 
(A) were quantified using ImageQuant 5.0 and represented as fold over mock. The 
data shown are representative of three independent experiments. !
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ABSTRACT 
The Type I Interferons are potent mediators of the innate immunity that play 
an important role to restrict alphavirus pathogenesis in vivo.  It is well known that 
pattern recognition receptors, such as the RIG-I-Like RNA helicases, initiate early 
and rapid IFN induction to clear various virus infections by directly shaping the 
downstream adaptive immunity.  The exact mechanism(s) of IFN induction in 
response to alphavirus infections, however, have not been fully characterized.  In 
this report, we demonstrate that a determinant located within the conserved 
nsP1/nsP2 cleavage site of Ross River Virus (RRV) leads to an overall increase in 
viral RNA synthesis, thus driving excess IFN induction independently of host 
macromolecular shutoff.  We further demonstrate in various deficient embryonic 
fibroblast cells that the RRV mutant drives excess IFN induction through IPS-1 
signaling and is dependent upon RIG-I and PKR, but not MDA-5.  Furthermore, we 
are able to identify that the RRV mutant synthesizes uncapped 26S RNAs, exposing 
5’-triphosphates that induce robust IRF-3 and RIG-I activation.  Therefore, our 
results demonstrate that a novel mutation within the RRV nonstructural proteins may 
interfere with the viral capping apparatus, thus generating increased amounts of 
uncapped 26S RNAs to mediate IFN induction through a RIG-I and/or PKR 
dependent pathway.  
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INTRODUCTION 
The Type I Interferon (IFN) system is a highly coordinated component of the 
host innate immunity, acting early in viral infection to prevent replication and spread.  
The antiviral strategies employed include activation of IFN stimulated genes (ISGs), 
such as the protein kinase R (PKR) or the 2’-5’-oligoadeny-late synthetases 
(OASs)/RNase L, to act directly on limiting virus replication or to the production of 
pro-inflammatory cytokines and chemokines that selectively direct the downstream 
adaptive response (42, 51).  Type I IFN induction is initiated by host sensing of 
various pattern-associated molecular patterns (PAMPs), such as double-stranded 
RNA (dsRNA) and single-stranded (ssRNA), by pattern recognition receptors 
(PRRs) during viral infection (2, 43, 54).  Therefore, an important emphasis has 
been placed on identifying the host sensors as well as the activating viral ligands to 
further our understanding to combat these viruses.  The known PRRs to recognize 
viral infections include the Toll-Like Receptors (TLRs), the RIG-I (retinoic acid-
inducible gene I)-Like RNA Helicases (RLHs), as well as the PKR and 2’-5’-
OAS/RNase L proteins.  The TLRs are transmembrane receptors that act at the cell 
surface or within endosomal compartments, recognizing various PAMPS such as 
lipopolysaccharides, CpG DNA, and viral RNA substrates to induce IFN and pro-
inflammatory cytokines (26).  TLR3 is the only known TLR to not utilize the MyD88 
co-adapter, instead using the TIR domain-containing adaptor molecule 1 (Ticam-1, 
also known as TRIF) to induce IFN in response to dsRNA (59).  The RIG-I-Like RNA 
helicases, on the other hand, are cytosolic sensors that recognize both dsRNA and 
ssRNA (25, 39).  RIG-I and MDA-5 (melanoma differentiation-associated antigen-5) 
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RNA helicases have been extensively studied and plays a direct role in IFN 
induction to several RNA viruses, such as Flaviviruses (9), Picornaviruses (16), and 
Influenza viruses (39).  The specific viral ligands to activate the RLHs, however, are 
less clear. 
RIG-I and MDA-5 are DExD/H box RNA helicases that encode two N-terminal 
Caspase Recruitment Domains (CARDS) and a C-terminal helicase/ATPase domain 
(60).  Upon activation, RIG-I and MDA-5 interact with the CARD domains of the IFN-
promoter stimulator 1 (IPS-1) (also known as MAVS/VISA/Cardif) present on the 
mitochondrial membranes (27, 31, 47, 57).  The CARD-CARD interactions then lead 
to recruitment of other signaling factors for the activation of the downstream 
TBK1/IKK-! and IKK kinases to induce IRF-3 and NF-"B mediated IFN induction 
(24).  RIG-I and MDA-5 can discriminate between different RNA ligands, thus 
diversifying the host’s response to various different viruses.  MDA-5 primarily 
recognizes long dsRNA segments as well as ssRNAs that form large secondary 
structures (25, 38).  The natural ligand for RIG-I is still being debated.  Recent 
reports have identified the presence of a 5’-triphoshpate moiety on ssRNA and 
dsRNAs to activate RIG-I (23, 37, 39).  Free 5’-triphosphates within the cytosol of a 
cell are generally made by virus replication.  Therefore, many viruses encode 
different mechanisms to shield the 5’-triphosphates from the host sensors.  Some 
examples are; expression of a viral antagonist, such as influenza NS1, to sequester 
the RNA from RIG-I (39) or to block RIG-I activation (12), removal of the 5’-
triphosphate, as found in Borna disease virus, to avoid RIG-I detection (19), or 
through the covalent attachment of a viral peptide, such as Picornavirus VPg, that 
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prevents RIG-I recognition (59).  Another mechanism is through the simple addition 
of a 7-methyl-guanosine cap, like those found on host mRNAs (23).  Viral RNA 
capping, thus serves as a dual function to protect RNAs from RIG-I sensing as well 
as to facilitate translation of viral proteins.  Although, the requirement of free 5’-
triphosphates to activate RIG-I have been found in studies utilizing in vitro 
transcribed RNAs, as well as viral RNAs directly isolated from infected cells, other 
synthetic RNAs without 5’-triphosphates have also been found to activate RIG-I.  
These studies include short dsRNA (poly I:C), 3’-monophophates generate by 
RNase L RNA cleavage , 5’-monophosphates , as well as poly U/A tracts found in 
the 3’-UTR of several flaviviruses (25, 30, 44, 53, 55).  In addition to the RIG-I-Like 
helicases, the PKR and 2’-5’-OAS/RNaseL ISGs also reside in the cytosol, 
recognizing dsRNA to mediate an antiviral signaling cascade.  Several studies have 
reported additional roles to induce Type I IFN.  PKR primarily recognizes dsRNA, 
although reports have suggested that it can recognize 5’-triphosphates on ssRNAs 
(34).  PKR can induce Type I IFN to several viruses, including West Nile Virus (15) 
and Vaccinia virus (62).  Although, the exact IFN induction pathways have not been 
clearly defined, it has been reported that PKR can signal through the IPS-1 pathway, 
thus connecting PKR to the RLRs (62).  Furthermore, upon activation, RNase L 
cleaves ssRNA and dsRNA that feedback into the RIG-I IFN induction pathway, thus 
amplifying the IFN response (30).  Altogether, the host employs numerous PRRs, 
with distinct RNA specificities, that ultimately converge to robustly induce IFN to 
combat the wide range of viruses it encounters.  
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Alphaviruses are single stranded positive sense RNA viruses that encode an 
11-12Kb genome.  The RNA genomes encode a 5’ cap structure and a Poly-
adenylate tail, thus mimicking host mRNAs for translation of its viral proteins (50).  
The genome consists of two open reading frames that encode for the nonstructural 
proteins as well as the structural proteins.  The structural proteins are further 
encoded under an internal 26S subgenomic promoter.  The nonstructural proteins 
make up the replication complex of this virus.  NsP1 is a methyltransferase that 
displays guanylyl-transferase activities to mediate viral RNA capping (1).  NsP2 is a 
multi-functional protein serving as the viral protease to mediate cleavage of the 
nonstructural polyprotein (28).  In addition to its role as a protease, NsP2 is also a 5’ 
triphosphatase that removes the 5’ #-phosphate from newly synthesized RNAs 
before the NsP1 protein attaches a 7-methyl-guanine cap (56).  NsP3 is a 
phosphoprotein, however, its function has not been clearly defined (7).  And nsP4 is 
the viral RNA-dependent-RNA polymerase (40).  Upon infection, the viral genome is 
translated to generate the nonstructural polyprotein, NsP1234, where nsP4 is 
immediately cleaved from the polyprotein by the Nsp2 protease.  Then, the NsP123 
polyprotein forms a complex with nsP4 to mediate minus strand RNA synthesis (48).  
After accumulation of minus sense RNA, the NsP123 polyprotein is further 
processed to the mature nsP1, nsP2, and nsP3 proteins (29).  The fully processed 
nsPs bind to the minus strand RNAs, switching to synthesis of the full length plus 
sense RNAs.  The mature nsPs also bind to the internal 26S subgenomic promoter 
to mediate the synthesis of the viral structural proteins.  The structural proteins then 
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encapsidate the full-length plus sense RNAs, forming new virion particles that are 
released from the cell. 
Alphaviruses are potent type I IFN inducers (11).  The mechanisms of IFN 
induction or the IFN pathways that mediate this response, however, are unclear.  It 
has been previously reported that a generalized mechanism of virus mediated host 
macromolecular shutoff counteracts the IFN responses to both Sindbis and 
Venezuelan Equine Encephalitis Virus (11, 14).  These studies demonstrate that 
alphavirus mutants that are defective for host macromolecular shutoff, are also 
robust IFN inducers.  However, recent studies suggest that in addition to host 
shutoff, there may be specific viral antagonists that act early to delay IFN induction 
until virus mediated shutoff is firmly established (4, 6, 49).  The efforts to identify 
these early IFN interactions are hampered though, due to how little is relatively 
known about the pattern recognition pathways that are mediating these responses.  
Recent studies with Sindbis and chikungunya viruses have demonstrated IFN 
induction is mediated through an IPS-1 dependent pathway, although the upstream 
RNA helicases seem to display different virus specificities.  Sindbis IFN induction 
seems dependent upon MDA-5 and PKR signaling, but not RIG-I (5).  Chikungunya, 
on the other hand, signals through both RIG-I and MDA-5 (45).  The RNA sensor 
differences may be due directly to the virus strain used, thus complicating efforts to 
characterize a model for alphavirus sensors and the viral ligands that mediate these 
responses.  
We have previously identified a virulence determinant within the neurovirulent 
Sindbis AR86 virus (20, 52).  The determinant is located within the conserved 
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nsP1/2 cleavage domain, affecting both processing of the nonstructural polyprotein 
as well as disregulating viral RNA synthesis (21).  The determinant is not specific to 
the Sindbis viruses as a similar mutation within another alphavirus, Ross River Virus, 
also leads to a mutant that displays increased RNA synthesis and induces IFN 
independently of virus mediated shutoff of host macromolecular syntheses (6).  In 
this report, we analyzed the Pattern Recognition Receptor pathways that are 
involved in recognizing the RRV A532V mutant virus. Thus far, we have identified 
that the IPS-1 signaling pathway is crucial for IFN induction as mouse embryonic 
fibroblast cells (MEFS) that are deficient for the IPS-1 molecule fail to induce IFN by 
both viruses.  Analysis of MEFS that are deficient for either the MDA-5 or RIG-I RNA 
helicases, or PKR, demonstrated that the majority of the IFN induction by the mutant 
virus is dependent upon both RIG-I and PKR, but independent of MDA-5.  Analysis 
of potential IFN inducing ligands demonstrated that the mutant viruses exhibited 
increased viral RNA synthesis leading to greater quantities of full-length genomic 
and subgenomic 26S RNAs within an infected cell, suggesting that disregulated viral 
RNA synthesis is at least partly responsible for this mutation’s effect on type I IFN 
induction. We have further determined that the viral 26S subgenomic RNAs from 
infected cells can activate IRF-3 and RIG-I and that activation was dependent upon 
phosphatase treatment.  Based upon these results, we found that the 26S RNAs 
made within the RRV mutant A532V are not efficiently capped, thereby exposing 5’-
tripohosphates that lead to RIG-I activation.  Altogether, these results link a novel 
mechanism of IFN induction directly to a disruption of the RNA synthetic processes 
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by making 26S uncapped RNAs, which in turns drives excess IFN induction through 
the RIG-I and PKR sensors. 
 
RESULTS 
The RRV A532V mutant induces IFN via IPS-1 dependent signaling, but 
independently of TICAM-1. 
Previous studies identified a mutation at the P3 position of the nsP1/nsP2 
cleavage domain that affects type I IFN induction by both Sindbis virus and Ross 
River virus (RRV) (6).  In the case of RRV, a virus where the P3 Alanine was 
changed to Valine (A532V) induced up to 100 fold higher levels of type I IFN than 
the wild type RRV.  This effect was independent of virus induced host 
macromolecular shutoff and also acted at the level of type I IFN induction, since the 
mutant virus exhibited enhanced IFN induction in type I IFN receptor deficient cells 
that are incapable of amplifying type I IFN induction through IFN receptor signaling 
(6).  Therefore, in order to more fully understand the mechanism by which the 
A532V mutation affects type I IFN induction, we set out to further define both the 
host pathways that recognize the mutant virus and the viral ligand(s) responsible for 
the enhanced IFN induction, with the goal of determining whether the mutant was 
simply a better inducer of the same pathways that recognize the wild type virus or 
was activating a completely different viral sensor than the wild type virus.   
 Several alphaviruses, including Sindbis virus (5, 16), Semliki Forest virus (3), 
and Chikungunya virus (45) have been shown to induce type I IFN in fibroblasts via 
the intracellular RNA sensors, RIG-I and MDA-5, that signal through the adaptor 
95 
molecule IPS-1.  Therefore, IPS-1 deficient MEFs were tested for their ability to 
respond to the RRV A532V-gfp mutant.  Wild type and IPS-1 deficient MEFS were 
infected with the wild type RRV-gfp (figure 3.1A) and A532V-gfp (figure 3.1B) mutant 
viruses and type I IFN induction assessed.  As indicated in figure 3.1C, the mutant 
RRV A532V-gfp virus induced greater than ~50 fold IFN in comparison to RRV-gfp.  
However, no IFN induction is observed in the IPS-1 deficient MEFS when infected 
by either virus.  These studies suggest that IPS-1 is essential for induction by both 
the wild type virus, as well as the excess IFN induction by the A532V mutant.  To 
further confirm the bioassay results, we analyzed IFN-! mRNA levels following 
infection of wild type versus IPS-1 deficient MEFs with either virus.  While the mutant 
virus induced more IFN-$ mRNA at 6 hours post-infection than the wild type virus in 
C57Bl/6 MEFS, neither virus elicited IFN-$ mRNA in the IPS-1 deficient MEFS 
(figure 3.1D).  In contrast to IPS-1’s essential role in mediating type I IFN induction 
by both the wild type and mutant viruses, we observed no role for the adaptor 
molecule TRIF/Ticam-1 (22) in this process (figure 3.2), suggesting that neither virus 
induces type I IFN through TLR3 in murine fibroblasts.  
 
MDA-5 and RIG-I contribute to the recognition of wild type RRV, but the excess 
type I IFN induction by the A532V mutant is RIG-I dependent and MDA-5 
independent. 
Given the essential role that IPS-1 plays in baseline type I IFN induction by 
the wild type RRV and the excess type I IFN induction by the mutant virus, we next 
assessed relative contribution of RIG-I and MDA-5 in recognizing both the wild type 
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and mutant viruses.  RIG-I or MDA-5 deficient MEFS (along with their wild type 
controls) were infected with the RRV-gfp and RRV A532V-gfp mutant viruses.  As 
demonstrated in figure 3.3A, MDA-5 contributes to the IFN induction by wild type 
RRV, as the overall IFN induction by RRV-gfp in MDA-5 deficient MEFs was 
significantly lower than that observed in wild type MEFS.  However, the MDA-5 
deficient MEFS still retained the ability to respond to the A532V mutant as measured 
by bioassay, indicating that while MDA-5 does contribute to the overall recognition of 
RRV, it is not required for the excess type I IFN induction by the A532V mutant.  
Therefore, we analyzed the IFN induction profile by both RRV-gfp and A532V-gfp 
viruses in RIG-I deficient MEFS.  As shown in figure 3.3B, RIG-I also contributes to 
type I IFN induction against the wild type virus, suggesting that both RIG-I and MDA-
5 contribute to viral recognition and type I IFN induction by the wild type RRV.  In 
contrast to the MDA-5 deficient cells, the A532V mutant was a poor inducer of type I 
IFN in RIG-I deficient cells, suggesting that RIG-I plays a major role in driving IFN 
induction in response to the A532V mutant.  However, while IPS-1 deficiency 
completely ablated type I IFN induction by both the wild type and mutant viruses, the 
mutant virus still elicited higher levels of type I IFN than the wild type virus in RIG-I 
deficient cells, suggesting that either MDA-5 might contribute to the residual excess 
type I IFN induction by the mutant virus in the absence of RIG-I, or another sensor 
was contributing to the type I IFN induction by the A532V mutant.   
 
PKR also contributes to RRV A532V IFN induction. 
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Though RIG-I and MDA-5 are thought to be the major RNA sensors that 
signal via the IPS-1 adaptor, recent work has shown that PKR can also contribute to 
type I IFN responses against both alphaviruses (5, 41) and flaviviruses (15), and 
PKR dependent type I IFN induction is also IPS-1 dependent (62).  Furthermore, 
RNase L has been shown to enhance RIG-I dependent type I IFN induction by 
degradation of viral and host RNAs to produce more RIG-I ligand (30).  Therefore we 
initially tested whether MEFs that were doubly deficient in PKR and RNase L (63) 
exhibited any defect in their response to either wild type RRV or the A532V mutant.  
As demonstrated in figure 3.4A, the excess IFN induction observed in the wild type 
MEFS by the A532V mutant is dependent upon PKR and/or RNase L.  To determine 
whether this effect reflected a role for either PKR or RNase L, or a role for both 
proteins, we assessed IFN induction following infection of PKR or RNase L single 
knockout MEFs with either the wild type or A532V mutant RRVs.  As demonstrated 
in figure 3.4B, PKR, but not RNase L, contributed to the IFN induction by the A532V 
mutant, since the A532V mutant continued to elicit high levels of type I IFN in RNase 
L deficient MEFs, but reduced type I IFN induction compared to wild type virus in 
PKR deficient cells.  Importantly, similar to our results with RIG-I deficient MEFs, 
though PKR deficiency resulted in a significant reduction in type I IFN induction by 
the mutant virus, the A532V-gfp virus still induced more type I IFN than the wild type 
virus in the PKR deficient cells.  These results suggest that both PKR and RIG-I 
contribute to the high level of type I IFN induction by the A532V mutant, and that 
these sensor molecules may synergize to drive high levels of type I IFN induction by 
the mutant virus.   
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The RRV A532V mutant displays increases synthesis of viral RNAs within 
infected cells. 
Both RIG-I and PKR have been shown to recognize free 5’ triphosphate 
groups on cytoplasmic RNAs (23, 34, 37, 46), while RIG-I has been shown to 
recognize conserved RNA secondary structures (54) and PKR recognizes double 
stranded RNA (36).  Given that a similar mutation at the P3 position of the 
nsP1/nsP2 cleavage domain of Sindbis virus has been shown to affect the kinetics 
of viral RNA synthesis, it was possible that the A532V mutant simply disregulated 
viral RNA synthesis to produce more ligand and thereby more efficiently activated 
both RIG-I and PKR.  Therefore, to assess the impact of the A532V mutation on viral 
RNA synthesis, BHK cells were infected with both the wild type RRV and mutant 
A532V viruses at an MOI of 10.0, which results in equivalent rates of infection by 
both viruses (data not shown) and total RNA were isolated at the indicated time-
points.  As shown in figure 3.5A, the RRV mutant displayed equivalent levels of the 
viral minus strand RNA at early times post-infection compared to the wild type virus.  
However, at later times post-infection, the A532V mutant produced more minus 
strand RNA than that of the wild type RRV.  This is highlighted in figure 3.5B by 
densitometry quantification of the viral minus strand RNA bands that have been 
normalized to $-actin to ensure equivalent RNA loading.  Furthermore, similar results 
were observed when analyzing full length genomic plus strand and the 26S 
subgenomic RNAs (figures 3.5C and 3.5D).  Overall, these results suggest that the 
nsP1 mutation, like that observed for the Sindbis mutant, does disregulate viral RNA 
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synthesis leading to increased production of viral RNAs by the mutant viruses over 
their wild type counterparts. 
 
26S RNAs isolated from RRV and RRV A532V infected cells differentially 
activate the IFN-! promoter.  
Disregulation of viral RNA synthesis by the A532V mutant resulting in 
increased production of viral RNA could provide more ligand for RIG-I and PKR, 
thereby resulting in excess type I IFN induction by the mutant virus.  However, given 
that MDA-5 also contributes to the IFN response against the wild type virus, if 
increased levels of viral RNA were the sole reason that the mutant virus elicits a 
more potent IFN response, it would stand to reason that MDA5 would also contribute 
to the enhanced type I IFN response against the mutant virus.  However, since only 
RIG-I and PKR were required for the enhanced IFN response by the viral mutant, 
this raised the possibility that in addition to driving increased viral RNA synthesis, the 
A532V mutation might also lead to modifications of the viral RNA that make it a 
better ligand specifically for RIG-I and/or MDA-5.  Therefore, we sought to determine 
whether the RNAs from RRV and RRV A532V infected cells differ in their ability to 
activate the IFN-$ promoter. To accomplish this, we utilized a luciferase assay in 
293 cells that were transiently transfected with an IFN-$-luciferase reporter.  For the 
RNA isolation, BHK-21 cells were either mock infected or infected with the RRV and 
RRV A532V mutant viruses at an MOI (10) and total RNAs were harvested 8 hours 
later.  The 8-hour timepoint best represents the time of peak RNA synthesis by the 
RRV A532V mutant, although we have tested RNAs isolated at 4 and 6 hours post 
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infection (data not shown).  Equal amounts of RNA were then titrated and 
transfected into the reporter cells.  As shown in figure 3.6A, the RNAs from both the 
RRV and A532V mutant activated the reporter to significantly higher levels than the 
RNAs from mock-infected cells, which is consistent with previous reports that PRRs 
do not respond to self RNAs (23).  Interestingly, the RNAs from the A532V infected 
cells are a better activator of the IFN-$-luciferase reporter than those of the wild type 
RRV and this induction was ablated if the RNA was previously treated with 
phosphatase (figure 3.6B), which suggests that free 5’ triphosphates on the RNA 
were responsible for this IFN induction.  This was also the case if the RNAs were 
introduced into cells overexpressing RIG-I, (figure 3.6C), suggesting that the RNA 
from the mutant virus infected cells was a more potent activator of RIG-I.  Similar 
results are also observed at 6 hours post infection, however, at 4 hours post 
infection, the total RNAs from both wild type RRV and A532V infected cells were 
equivalent at activating the IFN-$ reporter.  This is consistent with our Northern Blot 
analysis (figure 3.5) as enhanced RNA synthesis by the mutant occurs later in 
infection.   
While the above results suggest that RNA from cells infected with the mutant 
virus led to enhanced type I IFN induction compared to the wild type virus, given that 
higher levels of viral RNA were present in the preparations from the mutant virus-
infected cells, these studies did not directly assess whether RNAs derived from the 
mutant virus might be better ligands for RIG-I and/or PKR-mediated type I IFN 
induction.  Therefore, we initially tested whether the equivalent amounts of viral 
genome from the wild type or mutant viruses differed in their ability to elicit type I IFN 
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responses by extracting viral RNAs from RRV and A532V virion particles.  Equal 
amounts of virion RNA were then titrated and transfected into the reporter cells.  As 
demonstrated in figure 3.7, both RRV and A532V full length genomic RNAs 
activated the IFN-$-luciferase reporter equivalently, suggesting that the full length 
positive strand genomes of the wild type and mutant virus did not differ in their ability 
to induce type I IFN.   
 Though the results with full length genomic RNA demonstrated no difference 
in their capacity to activate the type I IFN system, these studies could not rule out a 
differential ability of the mutant virus 26S RNA or even minus strand RNA to elicit 
type I IFN induction.  Therefore, we sought to directly evaluate the ability of the 26S 
RNAs from the two viruses to activate the type I IFN system by isolating the 26 RNA 
from wild type and mutant virus infected cells and testing these RNAs in the 
luciferase assay.  To that end, we employed continuous sucrose gradient 
centrifugation to separate the full-length genomes from the shorter 26S RNAs.  As 
shown in figures 3.8A and 3.8B, total RNAs were harvested from Mock, RRV, or 
A532V infected BHK-21 cells at 8 hours post-infection.  The isolated RNAs were 
then fractionated through a 15-30% sucrose gradient as described in the materials 
and methods.  An aliquot from each fraction was analyzed on a RNA gel (figure 
3.8B).  As indicated, the full-length genomes and 26S RNAs were observed in the 
RRV and A532V infected cells but not in the Mock infected cells.  The full length 
RNAs for both viruses were present in fractions 6-8 while the 26S RNAs were 
present in fractions 12-14.  Most importantly, fractions 12-14 did appear to include 
carryover of full-length genomes.  Therefore, fractions 12-14 from each infected cell 
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preparation were pooled to concentrate the amount of 26S RNAs.  The 26S RNAs 
were then treated with CIP enzyme or CIP buffer only and equal amounts were 
transfected into L929 cells for analysis of IRF-3 phosphorylation.  As demonstrated 
in figure 3.8C, the isolated 26S RNAs from the A532V infected cells robustly induced 
IRF-3 phosphorylation compared to equivalent amounts of RNA from the wild type 
virus.  Furthermore, IRF-3 activation was dependent upon CIP treatment, suggesting 
that free 5’-triphosphates on uncapped 26S RNA produced by the mutant virus is a 
better ligand for RIG-I and/or PKR, thereby resulting in enhanced activation of the 
type I IFN system.  This hypothesis was further evaluated by testing the ability of 
these same RNAs to activate the IFN-$ luciferase reporter.  As shown in figure 3.8D, 
the A532V 26S RNA was a better inducer of RIG-I mediated induction of the IFN-$-
luc reporter than the 26S RNAs of the wild type RRV.   
To further demonstrate that the A532V mutation produces uncapped 26S 
RNAs within infected cells, we analyzed whether an antibody to the 5’-cap structure 
(anti-TMG from EMD) would immunoprecipitate the A532V 26S RNA.  As 
demonstrated in figure 3.9, both the wild type RRV and A532V 26S RNAs are readily 
detectable before incubation with the anti-TMG coated beads.  However, only the 
wild type RRV 26S RNA was detected in the anti-TMG bound fractions.  Both mock 
and A532V 26S RNAs did not bind to the beads, supporting our results that the 
A532V 26S RNAs are uncapped.  Also, to help rule out any non-specific RNA 
binding, a negative control was employed.  The negative control consist of in vitro 
transcribed 26S RNAs that do not contain a 5’-cap structure.  As seen in figure 3.9, 
the negative control did not bind to the beads, suggesting that antibody binding to 
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the 5’-cap structure is specific.  We further demonstrated that the presence of 
uncapped 26S RNAs also leads to lower protein translation.  We measured GFP 
expression levels using RRV replicon particles.  The replicon particles encode a 
single GFP gene behind the 26S promoter (supplemental figure 3.1A).  Therefore, 
L929 cells were infected with RRV replicon particles encoding either the wild type 
Alanine or Valine mutation at an MOI (5).  At 12 hours post-infection, all cells were 
analyzed for GFP expression by Flow cytometry analysis.  As demonstrated in the 
supplemental data (supplemental figures 3.1B and 3.1C), equal numbers of cells 
were infected by the wild type RRV and A532V replicon particles, however, the 
mean fluorescent intensity was lower in cells infected with the A532V replicon.  
Furthermore, similar to the results seen with RRV A532V viruses in our previous 
bioassays, the A532V replicon particles also induced more IFN production in 
comparison to the wild type (supplemental figure 3.1D).  Altogether, our data provide 
strong evidence that the A532V mutant affects type I IFN induction through effects 
on the viral capping apparatus, thereby resulting in the production of more uncapped 
26S RNA which serves as a better ligand for RIG-I and/or PKR.   
 
DISCUSSION 
Alphavirus interactions with the type I IFN system play a major role in 
regulating viral pathogenesis and understanding these interactions is essential for 
elucidating how these important pathogens evade the host response, establish 
infection, and cause disease.  Recent studies by several groups have identified key 
roles for the cytoplasmic RNA sensors RIG-I, MDA-5, and PKR in alphavirus 
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recognition and initiation of the type I IFN response (3, 5, 16, 45), while additional 
studies investigating alphavirus evasion of the IFN system have begun to elucidate 
both nonspecific and specific mechanisms by which these viruses evade both IFN 
induction and signaling (4, 11, 18, 49, 58).  Much of this latter work has focused on 
viral mutants that disrupt the virus’s ability to shut off host macromolecular synthesis, 
and studies with these viruses have strongly suggested that non-specific antagonism 
of host cell RNA and protein synthesis plays a key role in limiting type I IFN induction 
by the virus (11, 13, 18).  However, a growing body of evidence suggests that viral 
determinants that do not affect host cell macromolecular synthesis also regulate type 
I IFN induction and signaling (4, 6, 49), and relatively little is known about the 
mechanisms underlying these shutoff independent interactions between 
alphaviruses and the type I IFN system.  The studies presented here investigated 
the mechanism(s) by which a determinant in the alphavirus nonstructural proteins 
modulates viral type I IFN induction, both at the level of understanding which host 
sensors contribute to viral recognition and in identifying the viral ligands that drive 
these processes.  These studies confirm work by other groups demonstrating the 
three major cytoplasmic viral RNA sensors, RIG-I, MDA-5, and PKR contribute to the 
recognition of wild type alphaviruses, such as RRV, but that recognition of a mutant 
virus that induces very strong type I IFN responses is mediated by RIG-I and PKR, 
but not MDA-5 (figures 3.3 and 3.4).  Additional studies strongly suggest that the 
viral mutation leads to the generation of uncapped viral subgenomic RNA (figure 
3.9), thereby leading to the enhanced RIG-I/PKR dependent enhancement of type I 
IFN production.  Not only do these studies further define the mechanisms by which 
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the host senses alphavirus infection, but they further illustrate how a virulence 
determinant in the alphavirus nonstructural proteins interacts with the host type I IFN 
system to limit viral recognition by the host.   
The results presented here strongly suggest that the mutation within the 
nsP1/nsP2 cleavage domain disregulates viral RNA synthesis, resulting in the 
production of higher levels of all three viral RNA species (figure 3.5).  Furthermore, 
the viral 26S RNA, but not the genomic RNA produced by the mutant virus appears 
to be better ligand for RIG-I and IRF-3 activation (figures 3.8B and 3.8C).  
Additionally, IRF-3 activation was dependent upon the presence of a 5’-triphosphate 
(figure 3.8C).  Therefore, we have determined that the RRV A532V mutant, in 
addition to making more viral RNA species, also makes 26S RNAs that are capped 
less efficiently than the 26S RNA from the wild type virus (figure 3.9), making the 
mutant virus-derived 26S RNA a better ligand for RIG-I, and possibly PKR.  This is 
consistent with the known roles of nsP1 and nsP2 in capping of the viral genomic 
and 26S RNAs through the nsP1 methyl and guanyltransferase activities and the 5’ 
triphosphatase activities of nsP2 (1, 56).  Though our results suggest that this effect 
on capping is specific for the viral 26S RNA, and previous studies have suggested 
that the 26S cap structure differs from the genomic RNA cap (8, 10), further analysis 
is needed to determine whether the nsP1 532 mutation specifically affects 26S 
capping and not the cap status of the genomic RNA.   
It has been well established that both RIG-I and PKR can recognize free 5’ 
triphosphates present on ssRNAs and dsRNAs.  These are hallmark indicators of 
viral replicative intermediates as host mRNAs in the cytosol generally contain 7-
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methyl-guanosine (7mG) cap or a 5%-monophosphate, and the presence of uncapped 
RNAs in the cytosol is considered to be a marker of non-self leading to RIG-I and 
PKR activation (23, 35, 37).  However, it is possible that other modifications of the 
viral RNA also contribute to the excess type I IFN induction by the A532V mutant, 
the fact that phosphatase treatment ablates the ability of A532V-derived viral RNA to 
stimulate IRF3 activation strongly suggests that recognition of uncapped viral RNA is 
the major driver of type I IFN induction by the mutant virus.  Though RIG-I and PKR 
interactions with free 5’ triphosphate groups have been extensively studies at the 
biochemical level using cell free assays and at the cellular level by transfection of 
uncapped RNA ligands, to our knowledge, this is the first demonstration of a viral 
mutant where modulation of capping directly affects type I IFN induction.  This 
further supports that idea that cap dependent viruses that replicate in the cytosol 
need to optimize their RNA capping activity as a means of avoiding the activation of 
RIG-I and/or PKR in the cell.  In fact, a similar mutation at the P3 position of the 
nsP1/nsP2 cleavage site in Sindbis virus also results in modulation of type I IFN 
induction (6).  In the case of this virus, a virulent Sindbis virus strain, AR86, appears 
to have acquired a gain of function mutation that promotes viral neurovirulence in 
adult mice.  This virulence determinant, a Threonine in place of the consensus 
Sindbis virus Isoleucine at the P3 cleavage mutation increases virulence and 
decreases type I IFN induction.  It remains to be determined whether this mutation 
also affects capping activity and studies are currently underway to address this 
possibility.  
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In summary, our findings demonstrate that the RRV viruses induce IFN 
activation through the RIG-I, MDA-5, and PKR RNA receptors via the IPS-1 
signaling pathway.  Furthermore, although MDA-5 does contribute to the IFN 
induction pool mediated by the wild type RRV virus, we demonstrate that the RRV 
A532V mutant is primarily driving excess IFN induction through the RIG-I and PKR 
RNA receptors.  Additionally, we provide evidence that the RRV A532V mutant 
directly activates RIG-I through the production of an uncapped 26S RNA, thereby 
firmly establishing a mechanism in which the RRV A532V mutant drives excess IFN 
induction.  Altogether, we propose a model in which a virulence determinant located 
within the conserved nsP1/2 cleavage site disregulates RNA synthesis, leading to 
the increased quantity of viral 26S RNAs that are not efficiently capped, and driving 
activation of RIG-I and/or PKR IFN responses. These studies further our current 
understanding of alphavirus pathogenesis and help define the mechanism(s) of IFN 
induction.    
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MATERIALS AND METHODS 
Viruses, replicons, and cell culture:  The wild type RRV (pRR64) and mutant RRV 
A532V (pRR64-A532V) viruses were generated as previously described (6, 33).  A 
split-helper system was used to generate the RRV replicons (49).  Briefly, all 
plasmids were linearized and used as templates for in vitro transcription of the full 
length genomic RNAs using mMessage Machine SP6 Kit (Ambion).  Transcripts 
were electroporated into Baby Hamster Kidney cells (BHK-21) cells using a Bio-Rad 
electroporator.  The supernatants were harvested 24 hours post electroporation and 
clarified through centrifugation for 20 minutes at 3,000RPM.  The clarified 
supernatants were then concentrated through a 20% (w/v) sucrose/phosphate-
buffered saline (PBS) cushion at 72,000 &g by ultracentrifugation (4 h).  The pelleted 
viruses and replicons were resuspended in PBS and 0.1ml aliquots were stored at -
80°C.  All viruses were tittered by standard plaque assay performed on BHK-21 
cells.  The titers of the RRV replicons were determined by counting GFP positive 
cells in BHK-21 cells. 
 
BHK-21 and L929 murine fibroblast cells were maintained in minimum essential 
medium (MEM) alpha medium (Gibco) supplemented with 10% Tryptose phosphate 
broth, 10% Donor Calf Serum (DCS), L-glutamine, and penicillin/streptomycin.  
Human embryonic kidney (HEK 293s) cells were maintained Dulbecco's Modified 
Eagle Medium (DMEM, Gibco) supplemented with 10% Fetal Bovine Serum (FBS), 
L-glutamine, and penicillin/streptomycin.  The IPS-1-/-, RIG-I-/-, MDA-5-/- primary 
mouse embryonic fibroblast cells (and their wild type controls) were kindly provided 
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by Dr. M. Gale (University of Washington).  MEFS were maintained in DMEM 
(Gibco) supplemented with 10% FBS, L-glutamine, penicillin/streptomycin, and non-
essential amino acids.  All other primary MEFS were generated from ~13-15 day old 
embryos and maintained in DMEM/F12 media containing 10% FBS, 10% tryptose 
phosphate broth, L-glutamine, and 50 µg/ml of gentamicin (Gibco).  To generate the 
PKR and RNase L single deficient MEFS, Sv/129 wild type and PKR/RNase L 
doubly deficient (63) inbred mice were crossed to generate F1 heterozygous mice.  
The F1 generation was further crossed to generate F2 single deficient mice.  All 
mice were bred in house in accordance with all University of North Carolina at 
Chapel Hill Institutional Animal Care and Use Committee guidelines.  The genotypes 
of all mice were confirmed by genotype protocols.  The PKR primer sets were 
previously described in (63).  The RNase L primers used were: 5’-
GGAAGTCAGAGGACCGTTG-3’ and 5’-GACGTCAATGAGTGTGACG-3’.  The 
respective sizes are RNase L WT allele: ~319bp, RNase L KO allele: ~1.3kb, RNase 
L het: 0.3kb and 1.3kb. 
 
Northern Blot analysis:  BHK-21 cells seeded in 6 well dishes and either mock-
infected or infected with RRV and A532V viruses at an MOI (5) in viral inoculum 
(1XPBS supplemented with 1%DCS, and Ca2+ -Mg2+).  After 1 hour incubation at 
37°C, 2 ml of media was added directly to the inoculum.  At 8 hours post-infection, 
the media was removed and cells were washed once with 1X Phosphate Buffer 
Saline (PBS-Gibco).  The cells were then lysed with 1 ml of Trizol (Invitrogen) and 
total RNA was isolated using the PureLink RNA Mini Kit (Invitrogen) following the 
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manufacturer’s protocol.  Equal amounts of total RNA (as indicated) were denatured 
in glyoxal (BioRad) and dimethyl sulfoxide (DMSO-Sigma) for 1 hour at 50°C.  The 
RNA samples were analyzed on a 0.08% Sodium phosphate agarose gel.  The RNA 
samples were then transferred to a GeneScreen (Perkin Elmer) membrane by a 
capillary flow blotting system for a total of 48 hours.  The RNAs were UV-crosslink to 
the membrane using a HL-2000 HybriLinker (UVP Laboratory Products) 1200 
(x100µJ/cm2) for 30 seconds.  The membranes were incubated in Pre-hybridization 
buffer (50mM Tris, 3XSSC, 10XDenhardt’s, 0.1%SDS, 2µg/ml of sonicated 
denatured salmon testes DNA-Sigma) that has been diluted (1:1) with Deionized 
Formamide at 55°C for 5 hours.  Blots were then hybridized with 5x10^6 CPM of 32P 
labeled riboprobes specific for the RRV plus or minus strand as described in (32) or 
specific for $-actin (murine pTRI-$-actin, Ambion) at 55°C overnight.  Membranes 
were then washed three times with buffers (1XSSC with 0.1% SDS, 1XSSC, and 
0.1XSSC) in consecutive order for 15 minutes each at 68°C.  Membranes were then 
exposed to a phosphoimaging screen, scanned using a Storm Phosphoimager (GE 
Healthcare), and quantified using ImageQuant software (GE Healthcare). 
 
Type I IFN bioassays:  Type I IFN bioassays were performed as previously 
described.  Briefly, L929 cell were seeded in 96 well plates.  Sample supernatants, 
as well as a murine IFN-$ (Chemicon) standard, were acidified to a pH<2 with 2N 
HCL for 24 hours.  Then, supernatants and standards were neutralized to pH=7 with 
2N NaOH and UV-treated for 10 minutes to inactivate any residual virus.  The 
samples were then titrated into the L929 cells in serial 2-fold dilutions.  After 24 hour 
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incubation, encephalomyocarditis virus (EMVC) was added to all cells at 4x10^6 
PFU/ml.  Cell viability was determined using 3-(4, 5-Dimethylthiazol-2-yl)-2,5-
diphenylte- trazolium bromide (MTT, Sigma) assay.  The total amount of IFN in each 
well was determined by direct comparison to a known concentration of IFN standard 
that has been normalized to a reference by the National Institute of Heath. 
 
Quantitative real-time PCR analysis:  MEFs were seeded in 24-well dishes and 
infected with RRV viruses at an MOI (5).  After 6 hour post-infection, cells were 
washed once with 1X PBS, and lysed with 500ul of Trizol (Invitrogen).  Total RNA 
was purified as previously described.  An equal amount of RNA was reverse 
transcribed using random primers and superscript III RT (Invitrogen).  The cDNAs 
were analyzed on a Prism 7000 machine (Applied Biosystems) using Taqman 
primer/probe sets for IFN-$ and 18S rRNAs. 
 
RNA isolations and sucrose gradient centrifugation:  To isolate virion RNA, 
BHK-21 cells were seeded in 150mm dishes and infected with RRV and A532V 
viruses at an MOI (0.01).  Supernatants at 24 hours post-infection were harvested, 
clarified, and concentrated as previously described.  Concentrated virions were 
lysed and RNA extraction was performed using the MagMAX viral RNA isolation kit 
(Ambion).  RNAs were then stored at -20°C for later use.  To isolate RNAs from 
infected cells, BHK-21 cells were seeded in 6-well dishes and were mock infected or 
infected with RRV and A532V viruses at an MOI (10) for 1 hour.  After the 1 hour 
incubation, 2ml of normal media or media supplemented with 1ug/ml of Actinomycin 
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D was added to the virus inoculum.  At 8 hours post-infection, total RNAs from 
infected cells were harvested as previously described.  All RNAs were eluted in 
nuclease free water, aliquoted, and stored at -20°C.  The stored RNAs were then 
used as ligands in the luciferase assays and IRF-3 phosphorylation studies or further 
purified through 15-30% sucrose gradient centrifugation for isolation of the 26S 
RNAs.  A 15% and 30% (w/v) sucrose buffer (140mM NaCl, 10mM Tris-HCl pH=7.4, 
1mM EDTA) was prepared in nuclease free water.  Then, a sucrose gradient maker 
was employed to make 10 ml gradients.  Each gradient was overlayed with equal 
volumes of total RNAs from mock-infected or RRV and A532V infected cells.  The 
sucrose gradients were then centrifuged at 23,000 RPM for 7 hours at 4°C using a 
Sorvall Surespin 630 rotor.  Then, samples were fractionated and ethanol 
precipitated with 3M sodium acetate and 1mg/ml of yeast glycogen (Roche)).  An 
aliquot of each fraction was electrophoresed in TBE gels and stained with Ethidium 
Bromide for RNA analysis.  Fractions containing the 26S RNAs were pooled, 
aliquoted, and stored at -20°C. 
 
Luciferase assays:  Human RIG-I expression plasmids were constructed as 
previously described (61).  Briefly, HEK-293 cells were treated with IFN-$ (100 IU) 
for 24 hours.  Then, total RNA was isolated using Ultraspec RNA Isolation (Biotecx) 
followed by AMV Reverse Transcriptase PCR (Promega) using RIG-I specific 
primers for first strand synthesis.  An N-terminal FLAG tag was engineered on a 
forward PCR primer and FLAG-RIG-I was then assembled by overlap extension 
PCR cloned into pcDNA3.1+.  All plasmids were confirmed by sequencing at the 
113 
University of North Carolina at Chapel Hill Genome Analysis Facility.  For the 
Luciferase assay, HEK-293 cells were seeded in 48 well plates.  After over night 
incubation, 200ng of FLAG-RIG-I or an empty plasmid (pcDNA3.1+) were co-
transfected with 50ng of a plasmid encoding an IFN-beta promoter (kindly provided 
by Dr. J. Pagano, UNC-CH) driving the luciferase gene using Fugene 6 (Roche).  
Twenty-four hours post-transfection, HEK-293 cells were stimulated with 8ng of poly 
I:C (Invivogen) or with the indicated amounts of viral RNAs.  All RNA ligands were 
transfected with Lipofectamine 2000 (Invitrogen) and cells were lysed with 1X Cell 
Culture Lysis Buffer (Promega) 7 hours later.  Samples were then assayed and 
quantified for luciferase activity.  
  
CIP Treatment and IRF-3 phosphorylation studies:  Equal amounts of total RNA, 
26S RNAs, or poly I:C (Invivogen) were incubated with 1-2ul of alkaline phosphatase 
(CIP, New England Biolabs) or with buffer only for 1 hour at 37°C.  Then, RNAs were 
column purified using Invitrogen’s PureLink RNA Mini kit and eluted in nuclease free 
water.  L929 cells were seeded in 12 well plates.  One microgram of either CIP or 
buffer treated RNAs were transfected into the L929 cells and at the indicated 
timepoints, total cells were washed 1X with PBS, and lysed in NP40 lysis buffer 
containing protease and phosphatase inhibitors.  The amount of total protein in each 
sample was determined by Coomassie Plus (Bradford) Assay (Pierce).  Equal 
amounts of total protein were resolved on a 10% sodium dodecyl sulfate 
polyacrylamide gel (SDS-PAGE) followed by a transfer onto a PVDF membrane 
(Bio-Rad).  Anti-IRF-3 C-20 antibody (Santa Cruz) or anti-$-actin (Sigma) were used 
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as primary antibodies, followed by anti-goat antibody conjugated to a Horseradish 
peroxidase (HRP) secondary antibody.  All membranes were then coated with ECL 
Plus (Amersham) and exposed to film. 
 
RNA Immunoprecipitations:  Equal amounts of sucrose purified, 26S RNAs were 
immunoprecipitated with anti-mouse 2,2,7-trimethylguanosine monoclonal antibodies 
(anti-TMG) bound to agarose beads (EMD K121).  The in vitro transcribed 26S RNA 
control was generated from a linearized RRV Replicon helper plasmid using 
Ambion’s MEGAscript (SP6) protocol.  The following RNA IP assay was performed 
as previously described (17).  Briefly, mock, RRV, or A532V 26S RNAs were purified 
from ribosomal RNAs using a MicroPoly (A) Purist Kit (Ambion).  Then, the purified 
26S RNAs were equilibrated in RNA binding buffer supplemented with RNasin 
Ribonuclease Inhibitor (Promega) and incubated with the anti-TMG beads at 4°C for 
2 hours with continuous rocking.  The anti-TMG beads were spun at 2,000 RPM for 
2 minutes and washed three times to remove unbound RNAs.  The RNAs were 
eluted from the beads by incubation in elution buffer for 10 min at 60°C, followed by 
a phenol chloroform extraction.  To determine the presence of bound 26S RNAs, 2ul 
of recovered RNAs were used as templates for a reverse transcriptase-Polymerase 
Chain Reaction (RT-PCR) using oligo dT(20) primers and Superscript III RT 
(Invitrogen).  Specific primers for the E1 gene were used in the subsequent PCR 
analysis to determine bound 26S RNAs.  All PCR products were analyzed by gel 
electrophoresis. 
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Flow cytometry analysis:  BHK-21 cells were seeded in 24 well plates.  Cells were 
either mock-infected or infected with RRV-gfp and A532V-gfp viruses or the RRV 
and A532V Replicons at an MOI (5) in triplicate samples.  At 12 hours post-infection, 
the media was removed and cells were washed once with 1X PBS.  Cells were then 
incubated with Trypsin (Gibco) and fixed in 2% paraformaldehyde (PFA) overnight.  
GFP expressing cells were quantified using a CyAn Cytometer and Summit Software 
(Dako). 
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Figure 3.1.  The IPS-1 molecule is critical for RRV A532V mediated IFN 
induction.  Wild type C57BL/6x129Sv/Ev and C57BL/6x129Sv/Ev IPS-1-/- MEFS 
were either Mock infected or infected with RRV-gfp (A) and A532V-gfp (B) viruses at 
an MOI of 5.  Supernatants harvested at 24 hours post-infection were analyzed for 
type I IFN using an IFN bioassay as described previously.  C) The bioassay results 
in (A) and (B) are represented as the IFN fold induction of the RRV A532V mutant 
over that of wild type RRV.  The limit of detection in each bioassay was ~83 IFN 
Units/ml.  D) Total RNA was extracted from infected MEFS at 6 hour post-infection 
and analyzed by quantitative real-time PCR (Applied Biosystems) for IFN-$ 
message.  The data are represented as the fold induction over Mock infected cells 
and have been normalized to 18S rRNA.  All samples were analyzed in triplicate and 
error bars represent the standard error of the mean.  The ' values were determined 
by ANOVA statistical analysis. 
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Figure 3.2.  The RRV A532V mediated type I IFN induction is independent of 
TICAM-1.  C57BL/6 wild type and C57BL/6 TICAM-1-/- MEFS were either Mock 
infected or infected with RRV-gfp (A) and A532V-gfp (B) viruses at an MOI of 5.  
Supernatants at 24 hours post-infection were analyzed by an IFN bioassay.  C) The 
bioassay results in (A) and (B) are represented as the IFN fold induction of the RRV 
A532V mutant over that of wild type RRV.  The limit of detection was ~11 IFN 
Units/ml.  Samples were analyzed in triplicate and error bars represent the standard 
error of the mean. 
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FIGURE 3.3 
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Figure 3.3.  The RRV A532V mediated IFN induction is dependent upon RIG-I 
and not MDA-5.  A) Wild type and MDA-5-/- MEFS and B) Wild type and RIG-I-/- 
MEFS were either Mock infected or infected with RRV-gfp and A532V-gfp viruses at 
an MOI of 5.  Supernatants were harvested at 24 hours post-infection and analyzed 
for type I IFN using a bioassay.  The upper panels depict the RRV-gfp results, while 
the middle panels depict the A532V-gfp results.  The IFN fold induction of RRV 
A532V over that of wild type RRV in each corresponding MEF experiment is 
represented in the bottom panels.  The limit of detection in the bioassay was 6 IU/ml.  
Samples were analyzed in triplicate and error bars represent the standard error of 
the mean. 
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FIGURE 3.4 
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Figure 3.4.  PKR contributes to the RRV A532V IFN induction.  A) Sv129 wild 
type and Sv129 PKR and RNase L double deficient MEFS were either Mock infected 
or infected with RRV-gfp and A532V-gfp viruses at an MOI (5).  Bioassays were 
performed on supernatants harvested at 24 hours post-infection and the limit of 
detection was 61 IFN Units/ml. B) The bioassay result in (A) is represented as the 
fold IFN induction of the A532V mutant over wild type RRV.  C) Sv129 wild type, 
Sv129 PKR-/-, and Sv129 RNase L-/- single deficient MEFs were either Mock 
infected or infected with RRV-gfp and A532V-gfp viruses at an MOI of 5.  Bioassays 
were performed on supernatants harvested at 24 hours post-infection and the limit of 
detection for all bioassays was 11 IFN Units/ml.  All samples were analyzed in 
triplicate and error bars represent the standard error of the mean. 
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FIGURE 3.5 
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Figure 3.5.  The RRV A532V mutant displays increased full length minus, plus 
strand, and 26S RNA synthesis.  BHK-21 cells were either Mock infected or 
infected with RRV and RRV A532V viruses at an MOI of 10.  Total RNAs were 
isolated from infected cells at the indicated time points and analyzed by Northern 
Blot analyses.  A) Five micrograms of the total RNAs were analyzed for viral minus 
strand and $-actin RNAs.  C) Northern Blot analysis for full length plus strand and 
26S.  Equal amounts of RNA were analyzed between virus samples but varying 
amounts were used across time points.  Five micrograms per sample was used for 
the 4 hour time point, two micrograms was used for 6 hour time point, and one 
microgram was used for the 8 hour time point.  B and D) The levels of full length 
genomic (49S) and 26S subgenomic RNAs were determined by densitometry 
quantification and have been normalized to the amount of $–actin levels found within 
the same lane.  Each data point is represented as fold over Mock.  The data shown 
are representative of three independent experiments. 
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FIGURE 3.6 
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Figure 3.6.  The RRV A532V viral RNAs more robustly activate IFN induction.  
BHK-21 cells were either Mock infected or infected with RRV and A532V viruses at 
an MOI (10).  At 8 hours post-infection, total RNAs were isolated following 
Invitrogen’s PureLink RNA Mini Kit protocols and used in the following assays.  A) 
IFN-$-luciferase assay.  Briefly, 293 cells were transiently transfected with an IFN-$-
luciferase reporter along with the PCDNA3.1+ plasmid using Fugene 6 (Roche).  
After 24 hours, the indicated RNAs were transfected into the 293 cells and assayed 
7 hours later for luciferase activity.  B) IRF-3 phosphorylation assay.  Total RNAs 
were treated with or without CIP enzyme as described in the materials and methods.  
Then, equal amounts (1 microgram) were transfected into L929 cells.  At the times 
indicated, total cell lysates were harvested and equal proteins were loading onto an 
SDS-PAGE gel for Western Blot analysis.  Anti-IRF-3 C-20 (Santa Cruz) and anti-$-
actin (Sigma) antibodies, followed by anti-goat-HRP (Sigma) secondary were used 
to detect IRF-3 and $-actin proteins.  The arrows indicate phosphorylated IRF-3 (p-
IRF-3), total IRF-3 (IRF-3), and $-actin bands.  Samples are represented as 
M=Mock, P=poly I:C, R=RRV, and V=A532V.  C) RIG-I luciferase assay.  Equal 
amounts of total RNAs were titrated and then transfected into 293 cells transiently 
overexpressing a plasmid containing the human RIG-I gene or an empty plasmid 
(PCDNA3.1+) along with an IFN-$-luciferase reporter.  At 7 hours post-transfection, 
cells were lysed and assayed for luciferase activity.  All luciferase data were 
performed in triplicates and the error bars represent the standard error of the mean.  
The data are represented as the fold induction over PCDNA3.1+ control.  The ' 
values were determined by ANOVA analysis. 
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FIGURE 3.7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7.  The RRV A532V full length viral RNAs do not differently activate 
IFN induction.  Full length plus strand RNAs were isolated from RRV wild type and 
A532V mutant virion particles using Ambion’s MagMAX Viral RNA isolation kit.  After 
purification, equal amounts of RNA were titrated and transfected into the previously 
described RIG-I luciferase assay.  All data were performed in triplicates and the error 
bars represent the standard error of the mean.  The data are represented as the fold 
induction over PCDNA3.1+ control. 
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FIGURE 3.8 
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Figure 3.8.  The A532V viral 26S RNA is a better activator IFN inducer.  BHK 
cells were either Mock infected or infected with RRV and A532V viruses at an MOI 
of 10 in the presence or absence of 1ug/ml of Actinomycin D.  Total RNAs were 
isolated at 8 hours post-infection, layered on top of a 15-30% sucrose gradient, and 
centrifuged as described in the materials and methods.  After centrifugation, the 
gradients were fractionated in the order of bottom of the gradient (1) to the top (19 or 
20).  Any pellets formed were resuspended in buffer and indicated as (P).  A) RNA 
gel analysis of isolated total RNAs before sucrose gradient centrifugation.  B) RNA 
gel analysis of the sucrose gradient fractions.  The full length genomic RNAs (G) are 
indicated by a white arrow and the 26S RNAs (SG) are indicated by a black arrow.  
Fractions containing the 26S RNAs from (12-14) from the Mock, RRV, and A532V 
sucrose gradients were pooled, concentrated, and subsequently used in the 
following experiments.  C) Equal moles of 26S RNA were treated with CIP buffer or 
CIP enzyme and then transfected into L929 cells for IRF-3 phosphorylation analysis 
as previously described.  Samples are indicated as M=Mock, R=RRV, and 
V=A532V.  Data shown are a representative of two independent experiments.  D) 
Equal moles of 26S RNAs were titrated and transfected into HEK 293 cell for RIG-I 
luciferase assay analyses.  Each bar represents triplicate samples and the error bars 
represent the standard error of the mean. The ' values were determined by ANOVA 
analysis. 
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FIGURE 3.9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9.  The RRV A532V virus makes uncapped 26S RNA. 
Equal amounts of an in vitro transcribed 26S RNA or sucrose purified Mock, RRV, 
and A532V 26S RNA were immunoprecipitated (IP) with 2,2,7-trimethylguanosine 
monoclonal antibodies (EMD K121) as described in the materials and methods.  
200ng of starting 26S RNAs (input) or 2ul of IP RNAs were then subjected to RT-
PCR using an oligo dT (20) primer for CDNA synthesis.  5ul of each CDNA sample 
were then used for subsequent PCR amplification using virus specific primers for the 
E1 gene. 
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SUPPLEMENTAL FIGURE 3.1 
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Supplemental Figure 3.1.  GFP expression from the A532V encoded 26S RNAs 
is lower than those of the wild type RRV.  A) Schematic diagram of the RRV 
replicon genome encoding either the Alanine or Valine mutation followed by the GFP 
gene under a single 26S subgenomic promoter.  B, C, and D) L929 cells were either 
Mock infected or infected with RRV and A532V Replicon particles at an MOI of 5.  At 
24 hours post-infection, cells were harvested and analyzed for GFP expression by 
FLOW cytometry analysis.  B) Data depicts the percentage of cells infected and C) 
depicts the mean fluorescence intensity.  D) Supernatants from replicon infected 
L929 cells were analyzed for IFN ($ proteins using an L929 IFN bioassay.  All 
samples were done in triplicate and error bars represent the standard error of the 
mean.   
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 The type I IFN response plays a crucial role in controlling alphavirus 
infections.  These processes are highlighted by studies using animal models in 
which mice that are deficient for one or more IFN molecules, displayed increased 
susceptibility, replication, and tropism upon various alphavirus infections (16, 17, 24, 
25, 30).  Interestingly, specific alphavirus interactions with the host IFN response are 
poorly understood.  However, like many other viruses, it has been proposed that 
alphaviruses employ mechanisms to evade the host type I IFN.  These proposals 
are based upon in vivo mouse studies demonstrating that virulent alphaviruses can 
persist and cause mortality in mice even in the presence of an intact IFN system (7, 
13, 28, 30).  Furthermore, these studies suggest the presence of genetic 
determinants within alphaviruses that modulate the host IFN responses, since 
attenuating mutations within virulent viruses made them more susceptible to IFN 
actions.  Therefore, studies to identify the mechanism(s) of alphavirus IFN evasion, 
as well as the genetic determinants to modulate these processes, have been a high 
priority within the field.  In this dissertation, we explore the role of a single 
determinant located within the conserved nsP1/nsP2 cleavage domain of two 
different, but closely related alphaviruses, to modulate host IFN induction as well as 
to identify the mechanism(s) underlying these effects. 
 Heise et al. (2000) previously identified a unique genetic determinant located 
in the nsP1 protein, position 538, of the adult mouse neurovirulent Sindbis AR86 
virus (13).  This determinant lies in the P3 position within the conserved nsP1/2 
cleavage domain and was found to be essential for virus pathogenesis in vivo.  A 
single amino acid mutation of the determinant, resulting in a Threonine to Isoleucine 
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change, attenuates this virus resulting in restricted spread within the brains of 
infected mice.  The exact mechanism(s) by which this determinant regulates viral 
virulence, however, are not clearly defined.  Interestingly, the Thr to Ile change 
within Sindbis AR86 affected both the kinetics of nonstructural polyprotein 
processing and regulated 26S RNA synthesis.  Therefore, we hypothesized that an 
increase in RNA synthesis would lead to additional ligands that may more actively 
induce IFN.  As type I IFN plays a critical role to control alphavirus infections, we 
questioned whether the attenuated Isoleucine in Sindbis AR86 (T538I), would result 
in robust IFN responses, possibly initiating its clearance by the host immune 
response.  In accordance with this hypothesis, we found that the T538I mutant was a 
more robust IFN inducer in mice and in cell culture than the wild type Sindbis AR86 
virus.  As this determinant lies within the conserved nsP1/2 cleavage domain and 
was found to partially rescue virulence of other Sindbis viruses, this lead us to 
believe that the determinant would also modulate the IFN responses of other 
alphaviruses.  We found that a similar change, Alanine to Valine, within Ross River 
Virus (RRV) also induces robust IFN responses in vitro.  Although, we have yet to 
fully characterize the role of the Valine mutation on RRV pathogenesis in vivo, 
preliminary studies suggests that this mutant is also slightly attenuated (Cruz, C.C., 
Morrison, T.E., and Heise, M.T., unpublished data). Therefore, these studies 
highlight the role of a single determinant in modulating the host type I IFN response 
by two different alphaviruses, and suggest that at least in the case of Old World 
alphaviruses, this determinant is a major regulator of IFN responses and virulence.  
Therefore, it would be interesting to determine whether this determinant also affects 
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IFN induction by New World alphaviruses, such as Venezuelan Equine Encephalitis 
virus (VEEV).  If a similar mutation in VEE exhibits a similar effect on IFN induction, 
it would establish that this determinant plays a general role in regulating IFN 
induction by alphaviruses.  However, given that VEEV is known to interact with the 
host differently than that of the Old World alphaviruses (8), it is also likely that the 
nsP1 mutation may lead to different IFN results.  This would suggest that the nsP1 
determinant is unique to the Old World alphaviruses, and further studies to define 
this specificity would be needed. 
 Viruses employ many mechanisms to evade the host type I IFN response.  A 
major mechanism that has been proposed for alphaviruses is through shutoff of host 
RNA and protein synthesis.  Gorchakov et al. (2005) demonstrates that mutations 
within the nsP2 protein of a genetically related Sindbis virus leads to defective 
viruses incapable of inhibiting host cellular transcription and translation (10).  
Additionally, they found that their shutoff defective viruses also induced more type I 
IFN.  Although the mechanism(s) of host shutoff is not clearly defined, it is likely due 
to the translocation of free nsP2 to the nucleus to mediate transcription shutoff (11).  
Therefore, though our nsP1 mutation do not coincide with the positions of their nsP2 
mutations, it does lie within the nsP1/2 cleavage domain, potentially affecting either 
processing of the nonstructural polyprotein (nsP) or free nsP2 translocation to the 
nucleus.  However, we have found that the nsP1 mutations in both the Sindbis AR86 
(T538I) and RRV (A532V) did not adversely affect the host shutoff kinetics from that 
observed with the wild type viruses.  Further, we found that the Sindbis T538I, which 
displays increased kinetics of nsP processing, was a better inhibitor of host RNA and 
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protein synthesis than the wild type AR86 virus.  Additionally, we observed 
increased kinetics of IRF-3 phosphorylation upon infections with our nsP1 mutant 
viruses.  IRF-3 phosphorylation occurs independently of de novo protein synthesis 
(22) and should not be affected by virus mediated host shutoff.  Therefore, our 
studies suggest the mechanism(s) modulating the IFN responses by our mutants are 
independent of host shutoff processes.  We, however, are not the first to report 
shutoff independent IFN modulation.  Several studies have also reported similar 
findings using Semliki Forest Virus (SFV) and VEEV (4, 27).  Although we agree that 
global inhibition of host macromolecular synthesis to prevent initiation of the type I 
IFN response, while simultaneously favoring virus replication is a potent means to 
antagonize the IFN response, complete host shutoff does not occur until later times 
in the virus replication cycle.  Therefore, shutoff does not address potential early 
alphavirus interactions with the host type I IFN system.  Therefore, it is likely, that 
alphaviruses employ many mechanism(s), both specific and non-specific, to 
efficiently antagonize the host response.  We propose a biphasic model in which our 
nsP1 determinant acts early to specifically limit or evade the type I IFN response, 
until a second phase, mediated by host shutoff, takes over at later times. 
 There are several possibilities in which the nsP1 determinant could modulate 
the host type I IFN response.  One mechanism is that the wild type viruses encode 
an IFN antagonist that is directly inhibiting IFN induction or molecules within the 
signaling pathway.  This hypothesis correlates with previously identified roles for the 
nonstructural proteins of other alphaviruses to actively antagonize the IFN system 
(4, 27, 31).  Alternatively, another mechanism is that the nsP1 determinant may 
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delay viral 26S RNA synthesis in an attempt to avoid recognition by the host’s 
pattern recognition receptors until complete host shutoff has taken full effect.  This 
suggests that the 26S RNA is a target for PRRs to induce IFN.  Therefore, further 
experiments to test this theory are needed.  Additionally, the nsP1 mutation may 
disrupt mechanisms to properly cap the viral RNAs, as nsP1 and nsP2 make up the 
viral capping apparatus (1, 29).  As a result, uncapped RNAs are made, triggering 
IFN induction through the RIG-I and PKR pathways (14, 21).  Therefore, identifying 
the PRR pathways that are involved in IFN induction by the nsP1 mutant will further 
our understanding of the nsP1 determinant to modulate the host IFN responses. 
 Recent evidence suggests that alphaviruses could directly inhibit type I IFN 
responses.  In these studies, the authors demonstrate that the nonstructural proteins 
of Sindbis and VEEV can directly inhibit STAT-1 phosphorylation when stimulated 
with type I IFN (27, 31).  Interestingly, Simmons et al. (manuscript in progress) also 
demonstrates that the T538I mutation disrupts wild type Sindbis AR86 from 
efficiently blocking IFN-! stimulated STAT-1 activation.  Therefore, it is possible that 
the nsP1 determinant encodes an IFN antagonist that directly interferes with the IFN 
signaling pathway to limit IFN amplification and that insertion of Ile and Val into nsP1 
disrupts this activity, thus, accounting for the huge IFN differences observed in our 
earlier studies.  However, we found that infection with the nsP1 mutants of IFN-"! 
receptor deficient (or defective) cells, which cannot amplify IFN through the JAK-
STAT pathway, still induced more IFN than the wild type viruses.  Therefore, our 
nsP1 mutants were still capable of inducing IFN even in the absence of IFN 
amplification.  Interestingly, preliminary experiments suggest that wild type RRV, 
147 
unlike AR86, does not actively inhibit STAT-1 phosphorylation (Simmons, J.S. 
unpublished data).  Therefore, although, we cannot completely rule out a role for the 
nsP1 determinant in inhibition IFN signaling or that the determinant in Sindbis and 
RRV are acting through the same mechanisms, it is likely that our determinant is 
also modulating the IFN responses directly at the level of IFN induction.   
 In addition to the possibility that the nsP1 538 determinant is acting through 
JAK/STAT inhibition, it is also possible that our wild type viruses are actively 
suppressing initial IFN induction.  Breakwell et al. (2007) demonstrates, using a SFV 
nsP2 mutant, that the nsPs of SFV are able to suppress IFN induction, through a 
shutoff independent mechanism (4).  However, as they observe no difference in 
kinetics of IRF-3 activation between their viruses, they propose that antagonism 
occurs after IRF-3 translocation to the nucleus, which differs from our results. 
Therefore, it is likely that our nsP1 mutation is modulating IFN induction through a 
different mechanism than that observed with SFV and additional studies are needed 
to more fully address the possibility that either AR86 or RRV directly antagonize type 
I IFN induction. 
 Our data, thus far, suggests that the nsP1 determinant is modulating IFN 
directly at the level of IFN induction, possibly at steps prior to IRF-3 activation.  This 
is consistent with our hypothesis that the nsP1 mutants are generating more/or 
better RNA ligands to induce IFN.  As a first step in understanding how the nsP1 538 
determinant affects type I IFN induction, we set out to define the host pathways that 
contribute to type I IFN responses against either the wild type or mutant viruses.  
Specifically, we wanted to identify the PRRs that would respond to the nsP1 mutant 
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in hopes that identifying a specific PRR pathway would shed light on the 
mechanisms of IFN modulation and possible identifying potential viral RNA ligands.  
In the course of our studies, several different groups using Sindbis and chikungunya 
viruses reported that the IPS-1 pathway was important for alphavirus mediated IFN 
induction (5, 9, 26).  More specifically, Burke et al. (2009) reports that MDA-5, but 
not RIG-I, contributes to IFN induction by Sindbis where as Schilte et al. (2010) 
demonstrates that both RIG-I and MDA-5 responds to chikungunya virus (5, 26).  
Therefore, we evaluated the same PRR pathways to recognize the RRV A532V 
nsP1 mutant.  Similar to their reports, we also found that the IPS-1 molecule was 
critical for RRV A532V to mediate IFN induction.  Interestingly, while we 
demonstrate that both RIG-I and MDA-5 play a role in recognition of the wild type 
RRV, we found that RIG-I was required for the high level of IFN induction by the 
A532V mutant.  This led us to hypothesize that the A532V mutation may be 
modifying or overproducing an RNA that is a RIG-I specific ligand.  However, even in 
the absence of RIG-I, cells were still initiating low IFN responses to the RRV A532V 
mutant virus that were higher than the response mounted against the wild type virus.  
Although, this could be due to the actions of MDA-5, we could not rule out the 
possibility that another receptor was involved.  Therefore we analyzed the role of 
PKR as PKR has been shown to recognize uncapped RNAs and several reports 
demonstrate that PKR contributes to the IFN induction mediated by both Sindbis and 
SFV (3, 5, 25).  We found that like RIG-I, PKR also contributes to the IFN induction 
by the RRV A532V mutant.  Additionally, we were able to rule out a role for both 
RNase L and TICAM-1 to mediate IFN to our nsP1 mutant as these molecules have 
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also been implicated to play a role in IFN induction (6, 18).  Though we cannot rule 
out a role for other RNA receptors, such as TLRs, in recognition of the A532V 
mutant, our finding that IPS-1 is essential for A532V-mediated IFN induction strongly 
suggests that RIG-I and PKR are the major pattern recognition receptors responsible 
for IFN induction by the A532V mutant.  Although, we have yet to determine if RIG-I 
and/or PKR also play a role to recognize the Sindbis T538I mutant, preliminary 
studies demonstrate that the mutant also drives IFN induction through the IPS-1 
pathway (Cruz, C.C. and Heise, M.T., unpublished data).   
Previous studies suggested that the Sindbis virus nsP1 T538I mutant results 
in early induction of viral 26S RNA, therefore, we assessed whether this determinant 
also let to excess RNA synthesis in the context of RRV. Therefore, to further test our 
hypothesis, we evaluated kinetics of viral RNA synthesis with the RRV A532V 
mutant virus.  Similar to the T538I mutant, we also found a slight increase in overall 
26S RNA synthesis.  However, unlike Sindbis T538I, we also observed increased 
synthesis of full length minus and plus strand RNAs.  Therefore, it is likely that the 
RRV A532V mutant simply disregulates overall viral RNA synthesis, providing the 
host cell with additional ligands to induce IFN.  Although, additional analyses are 
needed to determine which specific RNA species is responsible for IFN induction 
and whether IFN induction is directly due to increased quantities of viral RNAs.   
 The fact that the nsP1 mutants display increased RNA synthesis, strongly 
supports our hypothesis that the nsP1 mutants are actively inducing type I IFN by 
overproducing potential ligands for RIG-I and/or PKR.  However, these results do not 
rule out the possibility that the nsP1 mutants also lead to the production of altered 
150 
RNAs that are able to serve as better ligands for either RIG-I or PKR.  Interestingly, 
it has been previously reported that free 5’-triphosphates present on uncapped 
RNAs can induce both RIG-I and PKR activation.  5’-triphosphates are indicators of 
viral replication as host mRNAs in the cytosol generally contain either a 5’-cap or a 
5#-monophosphate (20).  Therefore, host cellular RNAs are not recognized by RIG-I 
or PKR, allowing the RNA receptors to differentiate between self and non-self RNAs.  
Furthermore, viruses specifically remove the 5’-triphosphate on their RNAs (12) or 
attach a viral protein, such as VPg (32), or a 5’-cap (23) to the 5’-terminal end of its 
RNA in an attempt to disguise their RNAs from RIG-I detection, highlighting the fact 
that uncapped RNAs are potential viral ligands.  Given that nsP1 and nsP2 are 
involved in capping of viral RNAs, it was possible that the mutant was not only 
disregulating viral RNA synthesis, but that one or more of the viral RNAs was also 
capped less efficiently, thereby making it a better ligand for RIG-I and/or PKR.  
Therefore, to directly test this possibility, we first determined whether the RNAs from 
wild type and RRV A532V infected cells would differentially activate IRF-3.  We 
found that not only was the RNAs from A532V infected cells a better activator of 
IRF-3, but that activation was completely dependent upon the presence of a 
phosphate.  Furthermore, we determined that the same RNAs also differentially 
activated RIG-I.  Therefore, these studies support our hypothesis that the A532V 
mutant generates uncapped viral RNAs and that these RNAs are activating the RIG-
I/PKR pathway. 
 The previous studies firmly demonstrate that RRV A532V uncapped viral 
RNAs are activating RIG-I.  They have not, however, addressed the specific RNA 
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species that is mediating these responses.  Therefore, we found that the A532V 26S 
RNA, rather than the full-length genome, was responsible for differential RIG-I 
activation.  More importantly, IFN induction required a 5’-triphosphate and was a 
better RIG-I activator.  Altogether, these data suggested that the RRV A532V 
specifically makes uncapped 26S RNAs.  Given that the nsP1 and nsP2 proteins are 
involved in the capping of the viral RNAs, it is possible that the nsP1 mutation is 
disrupting the viral capping apparatus (1, 2, 19, 29).  The viral nsP2 protein is a 5’-
triphosphatase that removes a 5’-phosphate from the viral RNA as the nsP1 protein 
attaches a methylated cap.  Although our mutation does not lie within the reported 
catalytic domains of both nsP1 and nsP2, we cannot rule out an effect to disrupt the 
capping process.  Therefore, we assessed the presence of a 5’-cap structure 
between the wild type and A532V mutant 26S RNAs.  In line with our earlier results, 
we found that the RRV wild type RNA contained a 5’-cap whereas the A532V mutant 
did not.  These results were intriguing as we have previously observed delayed 
structural protein synthesis within the A532V infected cells and uncapped 26S RNAs 
would most likely explain these results.  To further confirm our results, we utilized a 
replicon particle system containing either the Ala or Val to launch GFP from a single 
26S promoter.  Similar to our earlier results, we also observed lower GFP protein 
expression from A532V (Replicon) 26S RNAs, further emphasizing that the RRV 
A532V mutant makes uncapped 26S RNAs.  Therefore, given our data, we 
demonstrate that in addition to making more viral RNA ligands, the A532V 
specifically makes uncapped RNAs to drive IFN induction through the RIG-I and/or 
PKR pathway.  Although our data suggests that the disruption of the capping 
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apparatus is specific for the 26S RNA, since we do not observe differential RIG-I 
activation with the full-length genomes, we cannot completely rule out an effect to 
modify the cap structures on the viral genomes.  Therefore, further analyses of the 
5’-cap structure on the full-length genomes are needed. 
 In summary, this dissertation provides novel insight into how a single 
virulence determinant modulates the host type I IFN response.  We found that 
mutation of the nsP1 determinant directly attenuates the virus, resulting in increased 
RNA synthesis, thus leading to its efficient recognition by the host RNA receptors to 
induce IFN induction.  We further demonstrate that in addition to an increase in 
potential RNA ligands, the nsP1 mutants also disrupt the viral capping apparatus, 
generating uncapped RNAs that drive excess IFN induction through the RIG-I and 
PKR sensors.  Furthermore, we propose that the nsP1 mutation specifically modifies 
the cap structures of the 26S RNAs, as the full length plus sense RNAs do not differ 
in their ability to activate IFN.  However, it should be noted that we have yet to 
assess the capacity of the negative sense or the dsRNA replicative intermediates, to 
activate IFN.  Although, given that the 26S RNAs are made in 5-molar excess to that 
of the full length RNAs (15), it is more likely that the 26S RNA is the target RIG-
I/PKR ligand.  This is not surprising, as our earlier studies with the Sindbis T538I 
mutant had indicated that the 26S RNA was a potential ligand.  Therefore, it would 
be interesting to determine whether the 26S RNAs of the Sindbis mutant are also 
uncapped and if those RNAs lead to more robust IFN inducers and whether the 
same pattern recognition receptors are involved.  These studies would further define 
the mechanism of IFN induction by the nsP1/nsP2 determinant as the Sindbis 
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viruses only differ in the quantity of 26S RNA, thus helping to rule out other RNA 
species.  Finally, as the nsP1/nsP2 mutation attenuates the neurovirulent Sindbis 
virus in vivo, defining the specific IFN interactions will further our understanding of 
the pathogenesis of this virus.  
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